The accuracy and completeness of ChatGPT in Belgian general practice: a descriptive analysis of therapeutic cases.

Devolder Nathalie, KU Leuven

Reynders Emma, KU Leuven

van Bijsterveld Aline, KU Leuven

Promotor: Prof. Dr. Aertgeerts Bert

Prof. Dr. Delvaux Nicolas

Master of Family Medicine

Masterproef Huisartsgeneeskunde
Academiejaar: 2024 – 2025

©Copyright by KU Leuven

Deze masterproef is een examendocument dat niet werd gecorrigeerd voor eventueel vastgestelde fouten. Met uitzondering van het door de wet toegestaan gebruik, is zonder voorafgaande schriftelijke toestemming van de auteur(s) het overnemen, kopiëren, gebruiken of realiseren van deze uitgave of gedeelten ervan verboden. Voor aanvragen tot of informatie in verband met het overnemen en/of gebruik van gedeelten uit deze publicatie, wendt u zich tot de KU Leuven, Faculteit Geneeskunde, Campus Gasthuisberg O&N2, Herestraat 49 – bus 400, 3000 Leuven.

Voorafgaande schriftelijke toestemming van de promotor(en) is eveneens vereist voor het aanwenden van de in dit afstudeerwerk beschreven (originele) methoden, producten en programma's voor commercieel nut en voor de inzending van deze publicatie ter deelname aan wetenschappelijke prijzen of wedstrijden.

Abstract

Background: Chat Generative Pre-Trained Transformer (ChatGPT) is an advanced large language model-based generative artificial intelligence that has gained widespread attention since its introduction in 2022. Its potential applications in medicine are currently under investigation. In the context of general practice, ChatGPT may facilitate the creation of patient education materials, development of informational pamphlets (e.g., voiding diaries, headache diaries, translated questionnaires), and enhancement of patient communication. Furthermore, it has potential utility in clinical decision-making by assisting with differential diagnosis expansion, triage, and therapeutic option exploration. However, limitations exist, particularly with the publicly available version of ChatGPT 3.5, which is constrained by training data up to September 2021, potentially leading to outdated medical information. In contrast, ChatGPT 4.0, accessible via subscription, has direct access to the internet, which may mitigate this limitation. Given these constraints, this study aims to evaluate the reliability and applicability of ChatGPT in the general practice, where inaccuracies may have critical consequences.

Methods: This study assessed the therapeutic capabilities of ChatGPT 3.5 and ChatGPT 4.0 using five therapeutic cases derived from general practice in Belgium. Each model was presented with the same cases three times to investigate reproducibility, and clinical queries were posed accordingly. The responses generated by ChatGPT were systematically compared with established guidelines from clinical databases. A Likert scale was employed to assess response accuracy (scored out of 5) and completeness (scored out of 3).

Results: For therapeutic accuracy, ChatGPT 3.5 achieved a mean score of 3.867 (SD = 1.187), indicating reasonably accurate therapeutic recommendations but with considerable variability. In contrast, ChatGPT 4.0 had a higher score of 4.667 (SD = 0.816), reflecting improved accuracy and reduced variability compared to ChatGPT 3.5.

For therapeutic completeness, ChatGPT 3.5 achieved a mean score of 2.667 (SD = 0.617), indicating that while therapeutic recommendations were moderately complete, there was some inconsistency. GPT 4.0 demonstrated a slight improvement with a mean score of 2.733 (SD = 0.458), suggesting enhanced completeness and greater consistency relative to ChatGPT 3.5.

Conclusion: This study highlights the potential and limitations of ChatGPT in a general practice setting. ChatGPT demonstrated moderate therapeutic accuracy, with ChatGPT 4.0 having more accurate predictions. However, these differences were not statistically significant. Both models exhibited good completeness, with similar scores.

The small sample size of this study suggests caution when interpreting these results, as it may introduce bias. To improve the reliability and generalizability of these findings, future research should involve larger sample sizes before it is applied in medical practice.

Nederlandstalig abstract

Achtergrond: Chat Generative Pre-Trained Transformer (ChatGPT) is artificiële intelligentie, gebaseerd op “advanced large language models”, dat sinds de introductie in 2022 een veelbesproken onderwerp is. De potentiële toepassingen in de geneeskunde worden momenteel onderzocht. In de huisartsgeneeskunde kan ChatGPT helpen bij het creëren van educatiemateriaal, de ontwikkeling van informatiefolders (bijv. plasdagboeken, hoofdpijndagboeken, vertaalde vragenlijsten) en het verbeteren van de communicatie met patiënten. Bovendien heeft het potentieel nut in klinische besluitvorming door te ondersteunen bij het uitbreiden van een diagnostisch landschap, triage en het verkennen van therapeutische opties. Er zijn echter beperkingen. Zo is er geen transparante bronvermelding. Daarnaast zijn de trainingsdata van de openbaar beschikbare versie van ChatGPT 3.5 beperkt tot september 2021, wat kan leiden tot verouderde medische informatie. In tegenstelling hiermee heeft ChatGPT 4.0, beschikbaar via abonnement, directe informatie via het internet, waardoor deze beperking mogelijks wordt verholpen. Gezien deze beperkingen heeft deze studie als doel de betrouwbaarheid en toepasbaarheid van ChatGPT in de huisartsgeneeskunde te evalueren, waar onnauwkeurigheden ernstige gevolgen kunnen hebben.

Methode: Deze studie beoordeelde de therapeutische capaciteiten van ChatGPT 3.5 en ChatGPT 4.0 aan de hand van vijf therapeutische casussen uit de Belgische huisartsgeneeskunde. Aan elk model werden de casussen drie keer gepresenteerd en klinische vragen werden gesteld. De door ChatGPT gegenereerde antwoorden werden systematisch vergeleken met richtlijnen uit klinische databases. Een Likertschaal werd gebruikt om de nauwkeurigheid (beoordeeld op 5) en de volledigheid (beoordeeld op 3) van de antwoorden te evalueren.

Resultaten: Wat betreft therapeutische nauwkeurigheid behaalde ChatGPT 3.5 een gemiddelde score van 3.867 (SD = 1.187), wat wijst op een redelijk accurate therapeutische nauwkeurigheid met aanzienlijke variabiliteit. In tegenstelling daarmee behaalde ChatGPT 4.0 een hogere score van 4.667 (SD = 0.816), wat wijst op betere nauwkeurigheid en minder variabiliteit ten opzichte van ChatGPT 3.5.

Wat betreft therapeutische volledigheid behaalde ChatGPT 3.5 een gemiddelde score van 2.667 (SD = 0.617), wat aangeeft dat hoewel therapeutische aanbevelingen matig volledig waren, er enige inconsistentie bestaat. ChatGPT 4.0 vertoonde een lichte verbetering met een gemiddelde score van 2.733 (SD = 0.458), wat wijst op een betere volledigheid en betere consistentie ten opzichte van ChatGPT 3.5.

Conclusie: Deze studie benadrukt het potentieel en de beperkingen van ChatGPT in de huisartsenpraktijk. ChatGPT toonde een matige therapeutische nauwkeurigheid, waarbij ChatGPT 4.0 meer accurate antwoorden gaf. Deze verschillen waren echter statistisch niet significant. Beide modellen vertoonden goede vergelijkbare volledigheid. De kleine steekproefgrootte van deze studie vraagt om voorzichtigheid bij de interpretatie van deze resultaten, aangezien dit ruimte geeft voor bias. Toekomstig onderzoek moet gebeuren met grotere steekproeven om de betrouwbaarheid van deze bevindingen te verbeteren voordat het in de medische praktijk kan worden toegepast.

Table of contents

Abstract 2

Nederlandstalig abstract 3

Table of contents 4

Introduction 6

Methodology 8

- Case Selection and Standardization 8
- Therapeutic Questioning and AI Response Evaluation 9
- Descriptive analysis 9
- Reproducibility Analysis 9

Results 11

- Methodology 11
- Accuracy 12
- Completeness 13
- Statistical Analysis 13
  - Summary statistics 13
  - Outliers Analysis 14
  - Paired t-test Analysis 15
  - Paired line plots 16
  - Difference plots 17

Discussion 18

- Overall findings 18
- Reproducibility 19
- ChatGPT 3.5 versus 4.0 19
- Limitations 20
- Overall conclusions 21

Conclusion 24

Acknowledgments 25

Conflicts of interest 26

Financial Disclosure 26

References 27

Approval research ethics committee 30
Addenda 31
Addendum 1: Template 31
Addendum 2: Likert Scale 32
Addendum 3: All scores by reader 33
Addendum 4: All cases with answers 33

Introduction

Artificial intelligence (AI) driven tools are developing at an ever-increasing speed and applications of these AI driven tools keep expanding ever since. (1)

A well-known example of an AI tool is ChatGPT, an AI-driven chatbot, which uses a large language model (LLM) and natural language processing (NLP). This technology enables users to ask questions and receive responses in a conversational manner, mimicking human dialogue. (2) NLP uses machine learning technology to interpret and comprehend human language. Using a large, predetermined dataset, this NLP software can process input, analyze intent and sentiment, and generate real-time responses. (3)

Big data is the umbrella term for all the sources utilized by artificial intelligence programs. It consists of extremely large datasets that can be analyzed computationally to identify patterns. In 2023, ChatGPT was trained on 570 GB of data, consisting of books, web texts, articles, etc.., in a machine learning method. (4,5) However, the specific datasets used for training ChatGPT remain undisclosed. ChatGPT does not provide source citations, and the program itself reports that "the specific references used to train ChatGPT are not publicly available, [...]." As a result, ChatGPT cannot independently assess the reliability of its sources. The data selection process is managed by OpenAI's research team, which applies quality control measures. (4) This lack of explicit source verification creates the risk of so-called AI hallucinations-generated content that is inaccurate, non-evidence-based, or entirely erroneous. The latest version, ChatGPT 4.0, has reportedly reduced this risk. (5,6)

ChatGPT is taking the world by storm. From a medical point of view, its potential applications are currently being explored. Within general practice, multiple possibilities arise for both physicians and patients. (7) Patients may use it to quickly request documents for specialists or insurance purposes, or seek clarification on medical information they did not fully understand during a previous consultation. Additionally, they may use ChatGPT to ask sensitive questions they might hesitate to pose to their physician.

For general practitioners, this technology could assist in creating patient education materials, developing informational pamphlets (such as voiding diaries, headache diaries, or translated questionnaires), and generating content to enhance patient communication. (8) It may also support clinical decision-making by expanding differential diagnoses, assisting in triage, drafting sick certificates, and composing letters to insurers requesting coverage for costly medications. Furthermore, ChatGPT has the potential to improve adherence to medical prescriptions by simplifying language and minimizing miscommunication. (9)

Although ChatGPT is trained on extensive datasets, it remains a generative model, which means its responses can sometimes be irrelevant or nonsensical. Another limitation of ChatGPT, and all NLP-based systems, is that their performance is constrained by the quality and scope of the training data. (10,11) The publicly available version of ChatGPT 3.5 is limited to data collected up to September 2021, which can lead to outdated information in dynamic fields such as medicine. ChatGPT 4.0, which requires a subscription, can connect to the internet, potentially overcoming this limitation. (4) Given

these constraints, it is crucial to assess whether ChatGPT can be reliably applied in the medical field, where errors may have serious consequences.

In this study, we focus on evaluating ChatGPT's ability to address complex and less commonly encountered primary care issues. The intervention involves comparing ChatGPT's responses with established medical sources, including BCFI (Belgisch Centrum voor Farmacotherapeutische Informatie) (12), NHG (Nederlands Huisartsen Genootschap) (13), Domus Medica (14) and UpToDate (15). By systematically evaluating ChatGPT's therapeutic accuracy, adherence to clinical guidelines, and response reproducibility, this study aims to provide insight into its potential role as a decision-support tool in general practice. The comparative analysis between ChatGPT 3.5 and ChatGPT 4.0 will further clarify the impact of model advancements on clinical reliability and utility.

Methodology

In this study, a selected number of cases from general practice in Belgium were presented to ChatGPT 3.5 and ChatGPT 4.0. Clinical questions were posed to each chatbot, and their responses were compared with expert opinions and/or information from clinical guidelines and databases.

This thesis was conducted alongside a parallel study by the same research team investigating the diagnostic capabilities of ChatGPT. However, the present study specifically explores its therapeutic potential.

Case Selection and Standardization

The cases used in this study were drawn from the researchers' own clinical practice and subsequently anonymized. Each researcher is a general practitioner (GP) trainee working within a Belgian general practice. Common primary care issues were selected, particularly those complicated by factors such as comorbidities and/or polypharmacy. A diverse range of patient populations was included to reflect real-world demographics (table 1).

To ensure consistency, one researcher (VS) centralized, compiled, and formatted the cases into a predefined template, standardizing their presentation. Brand names of medications and abbreviations were avoided. The cases were then entered into ChatGPT using this standardized template (Addendum 1). The following data were provided in a fixed order: nationality, age, gender, general practitioner, main complaint, medical history, medication use, and relevant clinical findings, including history, physical examination results, and additional investigations such as medical imaging and laboratory tests. All data were entered in English.

Case 1	Rotator cuff tear
Case 2	Sialolithiasis parotid gland
Case 3	Toxoplasmosis infection in pregnancy
Case 4	Contraception
Case 5	Diabetes

Table 1: List of therapeutic cases

Therapeutic Questioning and AI Response Evaluation

A standardized prompt was used to elicit therapeutic recommendations from ChatGPT, requesting specificity and adherence to medical guidelines where applicable: *"Give the possible treatment options and the preferred treatment. Be specific and incorporate any applicable guidelines."*

The AI-generated therapeutic recommendations were compared with self-generated answers derived from established clinical databases, including NHG, Domus Medica, the Belgian Centre for Pharmacotherapeutic Information (BCFI) and UpToDate. Preference was given to Dutch-language sources, such as BCFI and NHG, to align the findings with Belgian guidelines. When Dutch-language sources were incomplete or unavailable, English literature was consulted.

The accuracy and completeness of the AI answers in comparison to the self-generated answers were assessed using the Likert scale (Addendum 2). The accuracy scale is a five-point Likert scale and the completeness scale is a three-point Likert scale. In accordance with the therapeutic query, there is a different interpretation of the scores. If a medical error was advised in the therapeutic cases, particularly advice that potentially could harm the patient, the accuracy scale received a score of maximum 2/5.

This scale was chosen as it evaluates both accuracy and completeness of answers. Another advantage is that the Likert scale is user-friendly and easily applicable by different researchers.

Descriptive analysis

Each case was independently scored by two researchers (VBA and SN). Discrepancies between scores were discussed, and if consensus could not be reached, a third researcher (KL) provided a final evaluation. The score assigned by the third researcher (KL) was considered definitive.

To ensure methodological rigor, external statistical advice was sought during the study design and analysis phase, particularly for the interpretation of Likert-scale scoring and the reproducibility assessment.

Reproducibility Analysis

To assess the reproducibility of ChatGPT's responses over time, each case and its corresponding therapeutic question were entered into ChatGPT 3.5 three times at one-month intervals by one researcher (VS). This interval was chosen arbitrarily, as this version of ChatGPT is not actively updated.

For ChatGPT 4.0, the same cases were entered three times at two-day intervals by the same researcher (VS). This interval differs from the interval of ChatGPT 3.5, as ChatGPT 4.0 updates daily. The Likert scores were compared across these repeated entries to evaluate response stability. Descriptive

statistical analyses were used to examine differences over time. In addition, the following statistical analysis was used to compare ChatGPT 3.5 and 4.0.

The outlier analysis identified in the dataset reveals instances where ChatGPT models significantly deviated from the gold standard scores.

The Paired t-test was employed to compare the performance of ChatGPT 3.5 and ChatGPT 4.0 across two categories: diagnostic accuracy and diagnostic completeness. This method is appropriate as it allows for paired comparisons of scores from the same cases, reflecting the relative performance of the two models. Statistics represent the magnitude of the difference between ChatGPT 3.5 and ChatGPT 4.0 in each category. Higher values indicate larger discrepancies between the models. P-value indicates the probability of observing a difference as extreme as the one measured, assuming the null hypothesis (no difference between ChatGPT 3.5 and ChatGPT 4.0 is true). A threshold of $p < 0.05$ was used to determine statistical significance. The estimate reflects the mean difference between ChatGPT 3.5 and ChatGPT 4.0 scores for each category. Positive estimates indicate that ChatGPT 3.5 scored higher on average, whereas negative estimates indicate that ChatGPT 4.0 performed better.

Bar charts, paired line plots and difference plots were generated to visually represent the scores and assess reproducibility.

Results

Methodology

The five therapeutic prompts were created and entered into OpenAI by one of the researchers (VS). This was carried out three times in ChatGPT 3.5 on January 13, 2024, February 27, 2024, and April 30, 2024. Subsequently, after the launch of ChatGPT 4.0, the prompts were run again on November 5, November 7, and November 9, 2024.
The responses from ChatGPT were collected separately by date. These responses were then independently evaluated by two researchers (VBA and SN). Both therapeutic cases and diagnostic cases from the complementary thesis were assessed by the same researchers. The evaluation was based on the guidelines from NHG, BCFI, Uptodate and Domus Medica, followed in this specific order. Eventually, no relevant information was used in the assessments from the latter source.

After all readings were assessed by the first two researchers, a third researcher (KL) was involved to provide a third evaluation for the cases where the first two researchers had not reached the same score (Addendum 3). The assessment from the third researcher was considered the final score (Table 2).

Therapeutic cases

Score accuracy with ChatGPT 3.5

	Reading 1	Reading 2	Reading 3
Case 1	5	4	5
Case 2	4	5	4
Case 3	1	2	4
Case 4	4	5	4
Case 5	5	3	3

Score accuracy with ChatGPT 4.0

	Reading 1	Reading 2	Reading 3
Case 1	4	5	5
Case 2	5	2	5
Case 3	5	4	5
Case 4	5	5	5
Case 5	5	5	5

Score completeness with ChatGPT 3.5

	Reading 1	Reading 2	Reading 3
Case 1	3	3	3
Case 2	3	3	3
Case 3	1	3	2
Case 4	3	3	3
Case 5	2	3	2

Score completeness with ChatGPT 4.0

	Reading 1	Reading 2	Reading 3
Case 1	3	3	3
Case 2	3	3	3
Case 3	3	3	2
Case 4	2	2	2
Case 5	3	3	3

Table 2: Final scores for accuracy (maximum score 5) and completeness (maximum score 3) after evaluation by the three researchers in all cases at three different times (corresponding reading) for both ChatGPT 3.5 (left) and 4.0 (right).

Accuracy

The accuracy was assessed by evaluating the correctness of ChatGPT's output in comparison to medical guidelines, expressed as a percentage. If medical errors were made, they were sanctioned with a lower score of 1/5 or 2/5.

A difference between the accuracy scores for the ChatGPT 3.5 and 4.0 runs was that, in general, there was more variability in the scores for the 3.5 runs. The scores ranged from the minimum to the maximum score, while for the 4.0 runs, the scores varied between 2/5 and the maximum score, with no cases reaching a score of 3/5. For the 4.0 runs, there was a higher frequency of the maximum score of 5/5, achieved twelve times compared to five times in the 3.5 runs.
In total, the third researcher assessed three readings for the ChatGPT 3.5 runs and four cases for the 4.0 runs.

Several specific cases were selected to illustrate key patterns and highlight notable findings.

Case 2: Sialolithiasis
In filling out the second prompt, the diagnosis of sialolithiasis was not explicitly stated. Instead, treatment plans were provided for diagnoses other than the desired diagnosis, such as sialadenitis or acute parotitis, which impacted the assessment. Both the 3.5 and 4.0 runs had one reading each (the first and third readings, respectively) where various diagnoses were listed with corresponding treatments, including sialolithiasis. In reading 2 of the 4.0 run, the lowest score of 2/5 was given, as more than half of the information was incorrect.

Case 3: Toxoplasmosis
The 3.5 runs contained the only case that received the minimum score of 1/5 for accuracy. This was the first reading of case 3, which handled the therapeutic management of toxoplasmosis infection during pregnancy. According to the Likert scale, this indicated that “more than one therapeutic mistake was made.” Reasons for this low score included incorrect advice on follow-up care, referencing irrelevant recommendations, and non-concrete medication advice. This case received also a lower score than other cases in the second and third readings but still scored higher than the minimum score received in the first reading.
In contrast, for the 4.0 runs, this case achieved the maximum score twice. The second reading scored 4/5, as it was less complete than the other readings.

Case 5: Diabetes
Case 5, related to diabetes management, required a third assessment in both the 3.5 and 4.0 runs for two out of three readings. In the 3.5 runs, only the first reading received the maximum score, while in the 4.0 runs, all reading achieved the maximum score. For the second and third readings of the 3.5 runs, the researchers assessed more variable scores: one researcher deemed the readings to be >90% correct enough for a maximum score, while the second researcher rated a score of 3/5 on both readings, which meant 50-70% of the information was correct. The third researcher provided the final score of 3/5.

Completeness

The completeness was evaluated by assessing the presence of relevant components of the proposed therapeutic options in comparison to the guidelines, again expressed in percentages (Addendum 2).

In total, both the 3.5 and 4.0 runs had eleven out of fifteen readings that achieved the maximum score of 3/3 (>75% of all therapeutic components listed, potentially with additional suggestions). The remaining readings scored 2/3 (50-75% complete therapeutic information).
In the 3.5 runs, the third researcher only had to evaluate one reading for completeness, namely the third reading of case 5 on diabetes. In contrast, the third researcher assessed four readings on the 4.0 runs, of which three were for case 4 on contraception.

Several specific cases were selected to illustrate key patterns and highlight notable findings.

Case 3: Toxoplasmosis
Only in the 3.5 runs did the first reading of case 3, concerning the treatment of toxoplasmosis infection in pregnancy, receive the minimum score. It received a score of 1/5 for accuracy as well as a 1/3 for completeness for the same reasons mentioned earlier. Furthermore, the completeness scores of the second and third readings fluctuated, respectively 3/3 and 2/3. In comparison, the 4.0 runs achieved higher scores for this case, with twice a maximum score of 3/3 and once a score of 2/3.

Case 4: Contraception
Case 4 about contraception, received higher completeness scores for all three readings in the 3.5 runs compared to the 4.0 runs. In the first, there was unanimity between the two researchers regarding the score of 3/3. In the latter, a third evaluation was required for each of the three readings, with 2/3 being the final score since not all potential contraceptives were mentioned.

Case 5: Diabetes
Case 5 on diabetes management received lower completeness scores in the 3.5 runs (twice 2/3) than in the 4.0 runs, where the maximum score was always achieved. Reasons for not achieving the maximum score included the omission of lifestyle recommendations for anticoagulation based on the CHA_2DS_2-VASc score, which were mentioned in the other readings.

Statistical Analysis

Summary statistics

Score results were listed descriptively (mean, median, standard deviation (SD), interquartile range (IQR), and were compared between groups using paired-t-test.

Category	Mean GPT 3.5 (SD)	Median GPT 3.5 (IQR)	Mean GPT 4.0 (SD)	Median GPT 4.0 (IQR)	Mean Gold Standard (SD)	Median Gold Standard (IQR)
Therapeutic Accuracy	3.867 (1.187)	4 (1.5)	4.667 (0.816)	5 (0)	5 (0)	5 (0)
Therapeutic Completeness	2.667 (0.617)	3 (0.5)	2.733 (0.458)	3 (0.5)	3 (0)	3 (0)

Table 3: Means and medians for diagnostic accuracy and completeness for both GPT 3.5 and 4.0.

For therapeutic accuracy, the mean score of ChatGPT 3.5 was 3.867, but with large standard deviation (SD = 1.187), indicating reasonably accurate therapeutic recommendations but with substantial variability. In contrast ChatGPT 4.0 achieved a higher mean score of 4.667, and with smaller standard deviation (SD = 0.816), indicating more accurate predictions with lower variability compared to ChatGPT 3.5.
The median (IQR) scores further support this observation. ChatGPT 3.5 achieved a median (IQR) score of 4 (IQR = 1.5), suggesting accurate therapeutic recommendations with noticeable variability. ChatGPT 4.0 improved upon this, achieving a median score of 5 (IQR = 0), demonstrating highly accurate and consistent therapeutic predictions.

For therapeutic completeness, ChatGPT 3.5 achieved a mean score of 2.667 (SD = 0.617). The moderate variability suggests that ChatGPT 3.5 produced therapeutic recommendations that are somewhat incomplete and inconsistent. ChatGPT 4.0 had a slightly higher mean score of 2.733 (SD = 0.458), indicating better completeness and greater consistency than ChatGPT 3.5.
The median (IQR) score of ChatGPT 3.5 was 3 (IQR = 0.5), indicating complete therapeutic recommendations with low variability. ChatGPT 4.0 matched this score, suggesting similar performance with equal variability.

ChatGPT 4.0 demonstrated overall improvements in therapeutic cases compared to ChatGPT 3.5 with higher mean scores. This suggests that ChatGPT 4.0 is more reliable for generating accurate and complete therapeutic recommendations.
The median scores highlight that ChatGPT 4.0 demonstrated greater consistency across all categories compared to ChatGPT 3.5, particularly in therapeutic accuracy where it achieves perfect scores (median = 5, IQR = 0).

Outliers Analysis

Case Id	Reading	GPT 3.5	GPT 4.0	Gold Standard	Category
Case 2	Reading 2	5	2	5	Therapeutic Accuracy

Case 3	Reading 1	1	5	5	Therapeutic Accuracy
Case 3	Reading 2	2	4	5	Therapeutic Accuracy

Table 4: Outliers analysis, the outliers identified in the dataset reveal instances where ChatGPT models significantly deviated from the gold standard scores.

Table 4 depicts an outliers analysis. For example, in case 2 (reading 2) under therapeutic accuracy, ChatGPT 3.5 provided a perfect score (score 5), whereas ChatGPT 4.0 scored only 2, deviating substantially from the gold standard score of 5. Similarly in case 3 (reading 1), ChatGPT 3.5 scored as low as 1 while ChatGPT 4.0 achieved a perfect score (score 5), aligning with the gold standard. These discrepancies highlight variability in ChatGPT models' responses, particularly in challenging cases or scenarios requiring nuanced clinical judgement. Further investigation is warranted to understand the reasons behind these outliers and improve model performance.

Paired t-test Analysis

Category	**statistic**	**p-value**	**estimate**	**method**
Therapeutic Accuracy	-1,976607382	0,068126928	-0,8	Paired t-test
Therapeutic Completeness	-0,323229968	0,751298496	-0,066666667	Paired t-test

Table 5: Paired t-test analysis.

The results for therapeutic accuracy did not reach statistical significance ($p = 0.068$), despite ChatGPT 4.0 achieved slightly higher scores than ChatGPT 3.5. The mean difference of -0.800 suggests a trend favoring ChatGPT 4.0, but the evidence is insufficient to confirm a meaningful difference. For therapeutic completeness, no significant difference was observed ($p = 0.751$), and the mean difference of -0.067 indicates that ChatGPT 4.0's marginally higher scores are negligible and lack practical relevance.

Overall, the results indicate that ChatGPT 4.0 showed comparable performance in therapeutic categories with no statistically meaningful difference observed.

Paired line plots




Figure 1: Paired differences in ChatGPT 3.5 and ChatGPT 4.0 scores by category. The paired line plot illustrates the differences between ChatGPT 3.5 and ChatGPT 4.0 scores across individual cases for each category. Each line represents a paired observation for the same case, linking the scores from ChatGPT 3.5 and ChatGPT 4.0, with the x-axis indicating the model and the y-axis representing the score.

The lines in therapeutic accuracy exhibit an upward trend indicating that ChatGPT 4.0 tends to outperform ChatGPT 3.5, but with greater variability. This aligned with the statistical analysis which showed a higher mean score for ChatGPT 4.0 but did not reach statistical significance reflecting insufficient evidence for a meaningful difference.

A more balanced distribution is shown in therapeutic completeness with lines showing both upward and downward trends, indicating that there is no clear advantage for either model in this category. The lack of systematic trends in the lines corresponded to the negligible and non-significant mean difference between the models in the statistical analysis.

Overall ChatGPT 4.0 demonstrated slightly better therapeutic accuracy without statistical significance. However, the greater variability observed in therapeutic categories suggests less consistent performance across cases.

Difference plots




Figure 2: Differences between ChatGPT 3.5 and ChatGPT 4.0 scores by category. The difference plot highlights the variability in performance between ChatGPT 3.5 and ChatGPT 4.0 across individual cases within each category. Positive bars indicate higher scores for ChatGPT 3.5, while negative bars indicate higher scores for ChatGPT 4.0.

Therapeutic accuracy revealed mixed results, with several cases showing negative differences where ChatGPT 4.0 outperformed ChatGPT 3.5, reflecting its relative strength in therapeutic cases. Especially cases 3, 4 and 5 showed particularly large negative differences, highlighting ChatGPT 4.0 superior performance for these cases.

The differences in therapeutic completeness were more balanced with positive bars for some cases and negative bars for others. Case 4 showed a higher score for ChatGPT 3.5, while case 3 and 5 showed higher scores for ChatGPT 4.0. The relatively small magnitudes of the differences and their mixed directions reflected the statistical finding that there is no significant difference between the models in this category.

Overall, the plot emphasizes ChatGPT 4.0's strength in therapeutic accuracy, with a general consistency in completeness scores.

Discussion

Overall findings

ChatGPT demonstrated good accuracy in therapeutic cases, with a mean score of 3.867 for ChatGPT 3.5. The score for ChatGPT 4.0 was even higher, with a mean score of 4.667, indicating more accurate predictions than ChatGPT 3.5. For therapeutic completeness, the mean scores were 2.667 and 2.733 for ChatGPT 3.5 and ChatGPT 4.0, respectively.

In addition to examining its therapeutic capabilities, research is also being conducted on the diagnostic capabilities of the chatbot. Parallel to this study, a related study is conducted by the same research team, focusing on the accuracy and completeness of responses in diagnostic questioning. (16)

Overall, in this study the chatbot seems to perform well in answering therapeutic questions, often providing comprehensive recommendations that consider comorbidities effectively. However, in cases where it received lower scores, errors were primarily related to medication advice. Its recommendations did not always align with Belgian guidelines, which served as the basis for reviewer assessments. The lack of clarity regarding the chatbot's sources raises concerns about potential harm, making it challenging to rely on in clinical practice.

Other studies analyzing chatbot-generated medication advice highlight similar concerns. For example, a study evaluated ChatGPT's performance in clinical pharmacy practice comparing it to human pharmacists. (17) While ChatGPT performed well in drug counseling, it was significantly weaker in prescription review, patient medication education, adverse drug reaction (ADR) recognition, and ADR causality assessment. The AI demonstrated strong retrieval, information integration, and conversational abilities but struggled with complex reasoning, situational awareness, and personalized responses. Another similar study yielded more positive results. (18) The latter evaluated ChatGPT's ability to assist in medication therapy management by identifying drug interactions and providing management plans for complex clinical cases. Results showed that ChatGPT accurately identified drug interactions and offered reasonable management plans, though limitations existed in recommending alternative therapies and specific dosages.

In this current study, ChatGPT showed potential in providing accurate and comprehensive medical information. However, it still falls short of being entirely reliable. Numerous small-scale studies across various (sub)disciplines have already explored the potential of AI in managing different diagnoses. (19–23) Overall, based on the existing studies, it can be concluded that ChatGPT shows promise in providing accessible medical guidance but has limitations in accuracy, personalization, and handling complex cases. While it moderately aligns with clinical guidelines, it often lacks the nuanced judgment of experienced professionals. Caution is necessary, and its use should be supplemented by expert consultation, especially for severe or complex cases, until future models improve.

Similarly, a study evaluated ChatGPT's accuracy and completeness in answering 284 medical questions across various specialties. (24) Physicians rated responses on a Likert scale, finding that ChatGPT

provided largely accurate (median accuracy score: 5.5/6) and comprehensive (median completeness score: 3/3) answers. Accuracy varied slightly based on question difficulty but was similar for binary and descriptive questions. Notably, re-querying low-scoring answers after 8–17 days showed substantial improvement. While ChatGPT demonstrated strong performance, the study also highlights the need for further research and model development to address inaccuracies and enhance reliability in medical applications.

Reproducibility

Regarding reproducibility, it is important to note that identical prompts presented at different points in time can still yield varying responses from the chatbot. This variation may be reduced by configuring the chatbot to operate with a low temperature setting, which can enhance the consistency of its outputs. However, this parameter was not explored in the current study and default temperature was used.

The temperature setting in ChatGPT affects how creative or predictable its responses are. Low temperatures (0.0–0.3) produce more accurate and consistent answers, which is essential in medical contexts where reliability is critical. (4) Higher temperatures (0.7–1.0) lead to more creative but less predictable output, which may be unsuitable for healthcare. While temperature can be adjusted in ChatGPT 3.5 and ChatGPT 4 via the OpenAI API, it cannot be manually changed in the standard ChatGPT application, where it is set automatically by OpenAI.

ChatGPT 3.5 versus 4.0

Based on the current statistical analyses, ChatGPT 4.0 showed overall improvements in therapeutic cases compared to ChatGPT 3.5, with a higher mean score indicating more complete and more accurate responses. Studies comparing the clinical-decision-making abilities of ChatGPT 3.5 and ChatGPT 4.0 are limited. One such comparative study evaluated both models' responses to 176 real-world clinical questions, scoring them on accuracy, relevance, clarity, utility, and comprehensiveness and showed that ChatGPT 4.0 outperformed GPT 3.5 across all rating criteria. (25) Another study evaluated both ChatGPT versions in generating recommendations on critical care topics and concluded that ChatGPT 4.0 outperformed 3.5 in appropriateness, but there was no significant difference in consistency or readability. (26) Both models produced misinformation (“hallucinations”) and inconsistent responses, highlighting the risks of using LLMs without clinical oversight. It should be noted that the latter studies were conducted in secondary care settings. Primary care physicians and specialists tend to approach their patients from different perspectives, often following different sets of guidelines. There is a lack of research on ChatGPT's therapeutic and clinical-decision-making capabilities in primary care. Further studies are needed in this area before it can be considered applicable in this context.

Limitations

Despite the promising results of this current study, the scope of the conclusion is restricted by several limitations.

One major issue is the underpowered sample size and a lack of sufficient statistical expertise, which hinder robust analysis. Additionally, the absence of a formal validation mechanism to objectively assess the chatbot's accuracy introduces potential bias, as the evaluation relied on a self-developed Likert scale based on subjective ratings by physicians.

In line with this, another important consideration is interobserver bias, as two independent raters assessed each case, with a third assessor involved in cases of disagreement. Differences in strictness or leniency among raters could have influenced the score results. Interestingly, human errors—diagnoses overlooked by doctors but identified by the chatbot—were excluded from the scoring method, potentially impacting the overall evaluation.

The structured case templates employed in this study (Addendum 1) explicitly require that responses be formulated in accordance with current medical guidelines. These templates were developed by the researchers themselves, incorporating elements deemed essential to answering the study's research questions. Key components included the chief complaint, patient gender, nationality, medical history, medication use, clinical findings and technical investigations. However, whether this approach represents the optimal method for structuring case templates for ChatGPT remains uncertain.

This study reveals the importance of including a precise diagnosis when posing therapeutic questions to ChatGPT. One case within this study (case 2: Sialolithiasis) was characterized by an insufficiently defined diagnosis, which led to an overly broad response from the chatbot. This lack of clarity may have contributed to inconsistencies in the quality of responses and potentially compromised the chatbot's ability to generate accurate and comprehensive outputs. As a result, the accuracy and completeness scores in this study may have been adversely impacted. However, no standardized guidelines currently exist on how such templates should be constructed for chatbot-based medical questions.

Furthermore, the templates may not fully reflect real-world patients' queries. In practice, patients often lack the medical knowledge necessary to provide detailed and structured clinical information. As a result, chatbot responses in real-world scenarios may differ from those obtained using our predefined templates. This discrepancy highlights the need for further research into optimal structuring of case templates to ensure that they align more closely with real-life medical consultations.

A final important limitation of this study is the rapid and unprecedented pace at which the field of artificial intelligence is advancing. While these developments present exceptional opportunities, they also raise critical concerns regarding the long-term implications of AI in both research and practical applications. The accelerating evolution of AI models often exceeds the capacity of regulatory frameworks to keep pace. Consequently, the speed of progress frequently leads to the rapid

obsolescence of existing data.
Whereas ChatGPT 3.5 constituted the standard freely accessible version at the onset of the study, this has transitioned to a limited version of ChatGPT 4.0 in 2024.

Overall conclusions

Despite the great potential of LLMs such as ChatGPT, it is important to note that their integration into clinical practice and health-related services comes with significant technical, ethical, and regulatory challenges.

The reliability of LLMs is crucial in healthcare, where even minor errors can have serious consequences for patients. Concerns about their reliability stem from factors such as accuracy, consistency, interpretability, and the quality of the training data.

A major challenge is the "black box" nature of LLMs. (27,28) These models rely on complex neural networks with billions of parameters, and unlike traditional algorithms with explicit rules, they generate responses based on probabilistic patterns learned from vast datasets rather than engaging in true comprehension. In clinical settings, this lack of transparency is problematic, as medical decisions must be based on reliable and explainable reasoning. If an LLM misinterprets test results or provides inaccurate recommendations, there is often no clear way to audit or validate its decision-making process.

Another critical issue is the risk of hallucinations, where LLMs generate plausible but entirely false information. Unlike human experts who can verify claims against real-world knowledge, LLMs lack built-in fact-checking mechanisms which can be very dangerous in healthcare, where inaccurate medical advice or misinformation can have life-threatening consequences. (27–29) Moreover, LLMs can sometimes produce inconsistent answers when given slightly different prompts or contexts. This inconsistency is a result of how these models predict the most likely sequence of words based on patterns in the data, without having true comprehension or understanding. These variations in responses can make it difficult for healthcare professionals and patients to rely on these models for decision-making, highlighting the need for external validation when using LLMs in healthcare.

The quality and timeliness of the data used to train LLMs further complicate their reliability. (27,30,31) Many widely used models, including ChatGPT 3.5, are trained on outdated information, with some having a knowledge cutoff as far back as 2021. This makes them unreliable for accessing the latest medical advancements, a significant drawback in a field where rapid progress is constant. Moreover, much of the training data is sourced from publicly available websites rather than peer-reviewed, professionally validated materials. This increases the risk of incorrect or untrustworthy outputs, further underscoring the need for improved data curation and model transparency.

Bias is a significant issue when it comes to the application of LLMs in healthcare. (27,31) These models are trained on vast amounts of data generated by humans, which inherently includes human biases. The training data often reflects societal inequalities, such as gender, racial, and socioeconomic biases, which the models then learn and reproduce.

LLM biases can emerge at different stages. (30) First, there is bias in the data itself, such as underrepresentation of certain groups in medical research or the use of biased medical terminology. Second, the model's outputs can be biased due to the algorithms it uses, which may prioritize certain perspectives based on the structure of the training data. Additionally, the user base can influence biases, as healthcare providers or patients may unknowingly input data that steers the model toward biased outcomes. To mitigate these biases, it is essential to incorporate diverse and representative datasets and develop monitoring systems to detect and address bias in LLM outputs. One potential solution is the creation of domain-specific models, trained on more inclusive and specific medical data, which could help reduce these biases and improve the model's fairness and accuracy.

Privacy and security concerns are among the most pressing issues when using LLMs in healthcare. (27,32) Given the sensitive nature of health-related information, breaches of confidentiality could have serious legal and ethical consequences. Currently, most publicly available LLMs do not guarantee anonymity, which increases the risk of unauthorized access to patient data. The use of third-party LLMs, such as ChatGPT, to manage patient interactions introduces the possibility of inadvertently disclosing personal health information during processing. To address these concerns, healthcare organizations may need to implement strict protocols for anonymizing patient data before using it with LLMs. Alternatively, they may opt to use in-house, domain-specific models that do not require sharing external data. (32)

Medico-Legal complications could also arise by the lack of accountability for AI-generated medical advice, particularly if patients rely on inaccurate or harmful information. (33) Therefore, it is important not to blindly adopt the information provided by AI-generated systems like ChatGPT, but rather to approach these answers with a critical mindset and a solid knowledge of the subject.

Public acceptance and trust are also significant barriers to the widespread adoption of LLMs in healthcare. While some patients and healthcare professionals trust AI tools like ChatGPT for medical information, skepticism remains widespread. (30) A key factor contributing to this distrust is the lack of transparency about how these models operate and the fear of relying on technology that may produce inaccurate or biased results. Additionally, concerns about the security of personal health data further undermine confidence in LLMs. For LLMs to gain widespread adoption, both healthcare professionals and patients need to be educated about their benefits and risks. (29) It is crucial to provide proper training on using these tools safely and responsibly, ensuring that they complement human decision-making rather than replace it. Medical education should also include training on the limitations of AI tools and emphasize the importance of external validation when using these models.

Despite concerns surrounding their use, LLMs offer numerous potential benefits to the healthcare system. With further validation, LLMs have the potential to serve as valuable assets for quick medical information retrieval in fast-paced healthcare settings, improving healthcare efficiency and supporting complex decision-making. (29) While LLMs are not yet reliable enough for independent clinical decision-making, they can still aid healthcare providers by suggesting possible diagnoses or treatment options, which can be further validated by the clinician. (34) This can serve as a valuable tool for enhancing clinical decision support. LLMs can also be used to generate patient-friendly materials tailored to an individual's health literacy level and preferred language. (27,29) This helps improve

patient understanding and engagement, empowering them to take an active role in their own care. Additionally, LLMs can assist with administrative tasks by automating processes like generating clinical documentation, summarizing patient notes, or triaging patient queries. (32) This can reduce the administrative burden on healthcare professionals and improve efficiency within healthcare.

In conclusion, it is highly likely that LLMs, such as ChatGPT, will play a pivotal role in the evolution of medical decision-making within primary care. Currently, GP predominantly rely on the Evidence Linker to access relevant information. The Evidence Linker is an integrated tool within Electronic Health Records (EHR) that provides clinicians with evidence-based medical information during patient consultations. The potential of AI to enhance or even replace such tools lies in its ability to facilitate more rapid, context-specific data retrieval, offer real-time decision support, and continuously assimilate the latest medical research.

Further research should be focused on several key areas to maximize the potential of LLMs in healthcare.
Training LLMs on domain-specific datasets, including clinical notes, medical literature and even patient data could significantly enhance the accuracy and completeness in primary care medicine and prevent hallucinations. (27,30,34)
Rigorous clinical trials should be conducted to assess the performance and effectiveness of LLMs in improving healthcare outcomes. These trials should evaluate their impact on patient safety, diagnostic or therapeutic accuracy and completeness. Research into identifying and mitigating biases in LLMs is essential. It is crucial that these models do not perpetuate existing healthcare disparities, particularly with regard to race, gender, and socioeconomic status. Addressing biases will help ensure that LLMs provide equitable care and improve outcomes for all patients' populations. (27,30)

Conclusion

ChatGPT demonstrated good therapeutic accuracy and completeness for the presented medical cases. In this study ChatGPT 4.0 outperforms ChatGPT 3.5.

However, these differences were not statistically significant. The small sample size of this study suggests caution when interpreting these results, as it may introduce bias. As stated earlier, there are still numerous limitations of the chatbot itself. To improve the reliability and generalizability of these findings, future research is necessary.

Acknowledgments

We would like to express our gratitude to our promoters, Prof. Dr. Aertgeerts B. and Prof. Dr. Delvaux N. Thank you for the inspiration, advice and guidance through the steps of this project.

We would also like to thank the lectors for reading and evaluating this thesis.

Furthermore, we would like to thank and acknowledge Kerkhofs L., Stroobants N. and Vanpoecke S., who worked on a parallel thesis regarding the accuracy and completeness of ChatGPT in relation to diagnostic cases. We thank them for their smooth collaboration, which resulted in two theses providing valuable insights into both therapeutic and diagnostic challenges.

Special recognition goes to Pavlos Mamouris, who we thank for his insights on this project and helping us with the statistical analysis.

Conflicts of interest

None.

Financial Disclosure

The only financial support our thesis required was a one-month subscription to ChatGPT 4.0, which the researchers financed themselves.

References

1. Wiggers K, Corrall C, Silberling A, Park K. ChatGPT: Everything you need to know about the AI-powered chatbot [Internet]. 2023 [cited 2023 May 31]. Available from: https://techcrunch.com/2023/05/31/chatGPT-everything-you-need-to-know-about-the-open-ai-powered-chatbot

2. Ortiz S. What is ChatGPT and why does it matter? Here's everything you need to know [Internet]. 2024 [cited 2025 Apr 8]. Available from: https://www.zdnet.com/article/what-is-chatgpt-how-the-worlds-most-popular-ai-chatbot-can-benefit-you/

3. Amazon Web Services. What is NLP? - Natural Language Processing Explained [Internet]. 2023 [cited 2025 Apr 8]. Available from: https://aws.amazon.com/what-is/nlp/

4. OpenAI. OpenAI [Internet]. 2023 [cited 2025 Apr 8]. Available from: https://openai.com

5. Hughes A. GPT-3: Everything you need to know about OpenAI's GPT-3 tool [Internet]. 2023 [cited 2025 Apr 8]. Available from: https://www.sciencefocus.com/future-technology/gpt-3

6. Ackerson N. ChatGPT insists I am dead: The problem with language models [Internet]. 2023 [cited 2025 Apr 8]. Available from: https://towardsdatascience.com/chatgpt-insists-i-am-dead-and-the-problem-with-language-models-db5a36c22f11/

7. Weintraub K. ChatGPT is poised to upend medical information. For better and worse. [Internet]. 2023 [cited 2025 Apr 8]. Available from: https://eu.usatoday.com/story/news/health/2023/02/26/chatgpt-medical-care-doctors/11253952002/

8. Keymanthri M, Rennie S. ChatGPT has many uses: Experts explore what this means for healthcare and medical research [Internet]. 2023 [cited 2025 Apr 8]. Available from: https://theconversation.com/chatgpt-has-many-uses-experts-explore-what-this-means-for-healthcare-and-medical-research-200283

9. Will ChatGPT transform healthcare? Vol. 29, Nature Medicine. Nature Research; 2023. p. 505–6.

10. Culture Geek. ChatGPT: What is it and how does it work exactly? [Internet]. 2023 [cited 2025 Apr 8]. Available from: https://medium.com/geekculture/chatgpt-what-is-it-and-how-does-it-work-exactly-62e7010524d3

11. Pentalog. ChatGPT fundamentals [Internet]. 2023 [cited 2025 Apr 8]. Available from: https://www.pentalog.com/blog/tech-trends/chatgpt-fundamentals/

12. BCFI. Belgisch Centrum voor Farmacotherapeutische Informatie [Internet]. [cited 2025 Apr 8]. Available from: www.bcfi.be

13. Nederlands huisartsen genootschap. NHG [Internet]. [cited 2025 Apr 8]. Available from: www.nhg.org

14. Domus Medica. Domus Medica [Internet]. [cited 2025 Apr 8]. Available from: www.domusmedica.be

15. UpToDate. UpToDate Clinical Decision Support [Internet]. [cited 2025 Apr 8]. Available from: www.uptodate.com

16. Kerkhofs L, Stroobants N, Vanpoecke S. The accuracy and completeness of ChatGPT in Belgian general practice: a descriptive analysis of diagnostic cases. 2025;

17. Huang X, Estau D, Liu X, Yu Y, Qin J, Li Z. Evaluating the performance of ChatGPT in clinical pharmacy: A comparative study of ChatGPT and clinical pharmacists. Br J Clin Pharmacol. 2024 Jan;90(1):232–8;

18. Roosan D, Padua P, Khan R, Khan H, Verzosa C, Wu Y. Effectiveness of ChatGPT in clinical pharmacy and the role of artificial intelligence in medication therapy management. J Am Pharm Assoc (2003). 2024;64(2):422-428.e8.

19. Maillard A, Micheli G, Lefevre L, Guyonnet C, Poyart C, Canouï E, et al. Can Chatbot Artificial Intelligence Replace Infectious Diseases Physicians in the Management of Bloodstream Infections? A Prospective Cohort Study. Clin Infect Dis. 2024 Apr 10;78(4):825–32.

20. Dagher T, Dwyer EP, Baker HP, Kalidoss S, Strelzow JA. "Dr. AI Will See You Now": How Do ChatGPT-4 Treatment Recommendations Align With Orthopaedic Clinical Practice Guidelines? Clin Orthop Relat Res. 2024 Dec 1;482(12):2098–106.

21. Saturno M, Mejia MR, Ahmed W, Yu A, Duey A, Zaidat B, et al. Can generative artificial intelligence provide accurate medical advice?: a case of ChatGPT versus Congress of Neurological Surgeons management of acute cervical spine and spinal cord injuries clinical guidelines. Asian Spine J. 2025 Mar 4;

22. Lazris D, Schenker Y, Thomas TH. AI-Generated Content in Cancer Symptom Management: A Comparative Analysis Between ChatGPT and NCCN. J Pain Symptom Manage. 2024 Oct;68(4):e303–11.

23. Kahlon S, Sleet M, Sujka J, Docimo S, DuCoin C, Dimou F, et al. Evaluating the concordance of ChatGPT and physician recommendations for bariatric surgery. Can J Physiol Pharmacol. 2025 Feb 1;103(2):70–4.

24. Johnson D, Goodman R, Patrinely J, Stone C, Zimmerman E, Donald R, et al. Assessing the Accuracy and Reliability of AI-Generated Medical Responses: An Evaluation of the Chat-GPT Model. Res Sq. 2023 Feb 28;

25. Lahat A, Sharif K, Zoabi N, Shneor Patt Y, Sharif Y, Fisher L, et al. Assessing Generative Pretrained Transformers (GPT) in Clinical Decision-Making: Comparative Analysis of GPT-3.5 and GPT-4. J Med Internet Res. 2024 Jun 27;26:e54571.

26. Balta KY, Javidan AP, Walser E, Arntfield R, Prager R. Evaluating the Appropriateness, Consistency, and Readability of ChatGPT in Critical Care Recommendations. J Intensive Care Med. 2025 Feb;40(2):184–90.

27. Thirunavukarasu AJ, Ting DSJ, Elangovan K, Gutierrez L, Tan TF, Ting DSW. Large language models in medicine. Nat Med. 2023 Aug;29(8):1930–40.

28. Wang L, Wan Z, Ni C, Song Q, Li Y, Clayton EW, et al. A Systematic Review of ChatGPT and Other Conversational Large Language Models in Healthcare. medRxiv. 2024 Apr 27;

29. Goodman RS, Patrinely JR, Stone CA, Zimmerman E, Donald RR, Chang SS, et al. Accuracy and Reliability of Chatbot Responses to Physician Questions. JAMA Netw Open. 2023 Oct 2;6(10):e2336483.

30. Wang L, Wan Z, Ni C, Song Q, Li Y, Clayton E, et al. Applications and Concerns of ChatGPT and Other Conversational Large Language Models in Health Care: Systematic Review. J Med Internet Res. 2024 Nov 7;26:e22769.

31. Hirosawa T, Harada Y, Yokose M, Sakamoto T, Kawamura R, Shimizu T. Diagnostic Accuracy of Differential-Diagnosis Lists Generated by Generative Pretrained Transformer 3 Chatbot for Clinical Vignettes with Common Chief Complaints: A Pilot Study. Int J Environ Res Public Health. 2023 Feb 15;20(4).

32. Matulis J, McCoy R. Relief in Sight? Chatbots, In-baskets, and the Overwhelmed Primary Care Clinician. J Gen Intern Med. 2023 Sep;38(12):2808–15.

33. Dave T, Athaluri SA, Singh S. ChatGPT in medicine: an overview of its applications, advantages, limitations, future prospects, and ethical considerations. Front Artif Intell. 2023;6:1169595.

34. Andrew A. Potential applications and implications of large language models in primary care. Fam Med Community Health. 2024 Jan 30;12(Suppl 1).

Approval research ethics committee

Artificial intelligence, in de vorm van Chat-GPT, een troef in de klinische praktijk? Een vergelijking met EBM richtlijnen voor therapeutische vragen.

Dossiernr.:	MP028461
Masterproef:	Masterproef I HAIO, 2022-2025
Faculteit/opleiding:	Faculteit Geneeskunde - Master in de huisartsgeneeskunde
Studiefase:	eerste fase
Academiejaar:	2023-2024
Korte omschrijving / abstract:	**Deze literatuurstudie onderzoekt de bruikbaarheid en accuraatheid van ChatGPT, een AI gestuurde chatbot op basis van een large language model, in de huisartsenpraktijk. Dit wordt onderzocht aan de hand van fictieve casussen die worden getoetst aan het programma. De antwoorden worden beoordeeld op volledigheid en accuraatheid. Er wordt gekeken naar de toepasbaarheid in de praktijk, en of er geen belangrijke zaken gemist worden.**
Gewenste taal van communicatie:	nl
Promotor:	Prof Bert Aertgeerts (u0002409)
Copromotor:	Nicolas Delvaux (m9816943)
Organisatie:	KU Leuven
Dienst:	Academisch Centrum voor Huisartsgeneeskunde
Discipline:	Masterproef
Extra groepsleden:	Emma Reynders emma.reynders1@student.kuleuven.be r0611238 Aline van Bijsterveld aline.vanbijsterveld@student.kuleuven.be r0677547 Nathalie Devolder nathalie.devolder@student.kuleuven.be r0636540

De verstrekte informatie toont aan dat het onderzoek in het kader van de masterproef een zuivere literatuurstudie betreft en dat er op geen enkele wijze gebruik wordt gemaakt van proefdieren, proefpersonen of menselijk lichaamsmateriaal.

Dit type onderzoek vereist geen goedkeuring van een gemachtigde commissie voor medische ethiek.

Onder voorbehoud van de volledigheid en correctheid van de door u verstrekte gegevens, krijgt u hierbij het akkoord om het onderzoek in het kader van de masterproef te starten. Deze mail dient als bewijs van goedkeuring mocht u uw onderzoek wensen te publiceren.

Wij willen u erop attent maken dat u zelf verantwoordelijk blijft voor uw onderzoek. Bovendien doet elke wijziging aan de door u verstrekte gegevens omtrent de onderzoeksopzet deze goedkeuring vervallen. U dient in dat geval een amendement te maken aan uw huidig dossier.

Addenda

Addendum 1: Template

A Belgian #age year old #sex, visits the general practitioner with #complaint.

Symptoms and complaints:

Physical examination:

Technical examination:

Medical history:

Medication use:

Give the possible treatment options and the preferred treatment. Be specific and incorporate any applicable guidelines.

Addendum 2: Likert Scale

	THERAPEUTIC **(Control= guideline)**
Accuracy score	1. >1 medical error (*) 2. 1 medical error and further correct/more incorrect than correct information 3. > 50% correct 4. >70% correct 5. >90% correct (+-completely consistent with the guideline, nuance)
Completeness score	1. <50% complete (**) 2. 50-75% complete 3. >75% of all components listed, possibly +- additional proposals

(*) Medical error: advice that could potentially harm the patient

(**) Components of completeness/ accuracy therapeutic: non-drug therapy, drug therapy, indications for refer

Addendum 3: All scores by reader

Therapeutic cases

Score accuracy with chatgpt 3.5

	Reading 1			Reading 2			Reading 3		
	V.B.A.	S.N.	K.L.	V.B.A.	S.N.	K.L.	V.B.A.	S.N.	K.L.
Case 1	5	5		4	4		5	5	
Case 2	4	4		4	5	5	4	4	
Case 3	1	1		2	2		4	4	
Case 4	4	4		5	5		4	4	
Case 5	5	5		3	5	3	3	5	3

Score completeness with chatgpt 3.5

	Reading 1			Reading 2			Reading 3		
	V.B.A.	S.N.	K.L.	V.B.A.	S.N.	K.L.	V.B.A.	S.N.	K.L.
Case 1	3	3		3	3		3	3	
Case 2	3	3		3	3		3	3	
Case 3	1	1		3	3		2	2	
Case 4	3	3		3	3		3	3	
Case 5	2	2		3	3		2	3	2

Therapeutic cases

Score accuracy with chatgpt 4.0

	Reading 1			Reading 2			Reading 3		
	V.B.A.	S.N.	K.L.	V.B.A.	S.N.	K.L.	V.B.A.	S.N.	K.L.
Case 1	4	4		5	5		5	5	
Case 2	5	5		2	4	2	5	5	
Case 3	5	5		4	4		4	5	5
Case 4	5	5		5	5		5	5	
Case 5	4	5	5	4	5	5	5	5	

Score completeness with chatgpt 4.0

	Reading 1			Reading 2			Reading 3		
	V.B.A.	S.N.	K.L.	V.B.A.	S.N.	K.L.	V.B.A.	S.N.	K.L.
Case 1	3	3		3	3		3	3	
Case 2	3	3		3	3		3	3	
Case 3	3	3		3	3		2	3	2
Case 4	3	2	2	3	2	2	3	2	2
Case 5	3	3		3	3		3	3	

Addendum 4: All cases with answers

See separated files

Addendum: Case 1 Therapeutic Case 1: Rotator cuff tear

Chat GPT 3.5

A Belgian 74 year old male, visits the general practitioner with pain of the right shoulder.
symptoms and complaints: Pain in the right shoulder for 6 days. No clear origin, no trauma. slowly increasing in pain and discomfort
Physical examination: Swelling of the lateral side with a resolving hematoma beneath. Limited range of motion with exorotation limited more than abduction. Pain at the insertion of the biceps tendon
Technical examination: Ultrasound of the right shoulder. Complete tear of the supraspinatus tendon. Increased fluid in the bursa subacromialis subdeltoidea
Medical history: prostate carcinoma with bone metastasis, atrial fibrillation, Myocardinfarct
Medication use: Dutasteride/tamsulosine 0,5-0,4mg 1x/d ramipril 5mg 1x/d diltiazem 180 mg 1x/d rivaroxaban 20 mg 1x/d amiodarone 200 mg 1x/d gosereline LA 10,8 1x/3m calcium carbonate colecalciferol 1000mg/880E 1x/d

Give the possible treatment options and the preferred treatment. Be specific and incorporate any applicable guidelines

Answer 2024-01-13

Given the patient's age, medical history, and the identified complete tear of the supraspinatus tendon, the treatment options for this Belgian 74-year-old male with shoulder pain may include conservative management and surgical intervention. However, it's important to consider the patient's overall health and medical conditions, including prostate carcinoma with bone metastasis, atrial fibrillation, and a history of myocardial infarction.

1. **Conservative Management:**
   - **Pain Management:** Nonsteroidal anti-inflammatory drugs (NSAIDs) or acetaminophen can be considered for pain relief, keeping in mind the patient's cardiovascular history and current medications.
   - **Physical Therapy:** Physical therapy may help improve shoulder function and reduce pain. Range of motion exercises and strengthening exercises for the surrounding muscles may be prescribed.

2. **Surgical Intervention:**
   - Given the complete tear of the supraspinatus tendon, surgical options may be considered, especially if conservative management fails to provide adequate relief.
   - Surgical repair of the tendon might be recommended. This could involve arthroscopic techniques or open surgery, depending on the severity of the tear and the surgeon's preference.

3. **Considerations and Precautions:**
   - The patient's prostate carcinoma with bone metastasis suggests a careful evaluation of the overall health status. Any surgical intervention should be weighed against the potential risks and benefits, considering the patient's current health condition and life expectancy.

- Due to the patient's atrial fibrillation and the use of anticoagulant medication (rivaroxaban), precautions need to be taken to minimize bleeding risks during any surgical procedure. Close coordination with the patient's cardiologist or internist is crucial.

4. **Guidelines:**
   - The treatment plan should align with relevant clinical guidelines for managing rotator cuff tears. Guidelines from organizations such as the American Academy of Orthopaedic Surgeons (AAOS) or other national orthopedic associations can provide evidence-based recommendations.

5. **Multidisciplinary Approach:**
   - Given the patient's complex medical history, a multidisciplinary approach involving orthopedic specialists, cardiologists, and oncologists may be necessary to ensure comprehensive and coordinated care.

6. **Patient Communication:**
   - Clear communication with the patient regarding the potential risks, benefits, and expected outcomes of both conservative and surgical options is crucial. Shared decision-making should be encouraged, taking into account the patient's preferences and values.

Ultimately, the preferred treatment option should be determined through a collaborative discussion between the patient, the general practitioner, and relevant specialists, considering the patient's overall health and preferences.

Answer 2024-02-27

Given the patient's presentation of a complete tear of the supraspinatus tendon with associated symptoms and medical history, treatment options and preferences may need to be carefully considered. Here are some possible treatment options:

1. **Conservative Management:**
   - Pain management with nonsteroidal anti-inflammatory drugs (NSAIDs) or acetaminophen.
   - Physical therapy focusing on range of motion exercises, strengthening exercises for surrounding muscles, and modalities such as ultrasound or electrical stimulation.
   - Corticosteroid injections into the subacromial bursa for pain relief and reduction of inflammation.

2. **Surgical Intervention:**
   - Arthroscopic repair of the supraspinatus tendon tear may be indicated if conservative measures fail to alleviate symptoms or if there are functional limitations affecting the patient's daily activities.
   - Given the patient's age and medical history, the risks and benefits of surgery should be carefully weighed, considering factors such as anesthesia tolerance, risk of postoperative complications, and potential impact on quality of life.

3. **Biological Therapy:**
   - Platelet-rich plasma (PRP) injections may be considered to promote tissue healing and reduce inflammation, particularly in cases where surgery is not a preferred option or in patients with significant comorbidities.

4. **Medication Adjustment:**

- Review the patient's current medication list and consider any potential drug interactions or contraindications with medications commonly used for pain management or postoperative care.
- Consultation with a pharmacist or specialist may be necessary to optimize the medication regimen, particularly in patients with multiple comorbidities.

Preferred Treatment:
Considering the patient's age, medical history including prostate carcinoma with bone metastasis, atrial fibrillation, and myocardial infarction, as well as the presence of a complete tear of the supraspinatus tendon, the preferred treatment would likely involve a combination of conservative management and surgical intervention if indicated. However, due to the significant medical complexities and potential risks associated with surgery in this patient population, conservative management with physical therapy and pain management may initially be preferred, with close monitoring for symptom progression or functional limitations. Surgical intervention can be considered if conservative measures fail to provide adequate relief or if there is evidence of worsening symptoms or functional impairment over time. Close coordination with the patient's primary care physician, orthopedic surgeon, and other specialists involved in the patient's care is essential to ensure a comprehensive and individualized treatment approach.

Answer 2024-04-30

Given the medical history and the specific findings of a complete tear of the supraspinatus tendon, the treatment options for this patient would need to be carefully considered, taking into account his overall health status and existing conditions.

1. **Non-Surgical Management**:
   - **Physical Therapy**: This can be considered to help maintain joint mobility and function. However, the efficacy of conservative management in complete supraspinatus tears, especially in elderly patients, is often limited.
   - **Pain Management**: Use of analgesics or nonsteroidal anti-inflammatory drugs (NSAIDs) can help manage pain and inflammation.

2. **Surgical Intervention**:
   - **Arthroscopic Repair**: The preferred treatment for a complete tear of the supraspinatus tendon is surgical repair, particularly if the patient is healthy enough to undergo surgery and desires functional improvement.

Given this patient's complex medical history, including prostate carcinoma with bone metastasis and cardiovascular issues, a comprehensive evaluation by an orthopedic surgeon would be crucial to determine the feasibility and risks of surgery. Guidelines typically recommend surgical intervention for symptomatic complete tears of the supraspinatus tendon, particularly when there is significant functional impairment.

In this case, due to the patient's pain and the impact on shoulder function, along with the desire to optimize quality of life, surgical repair may be the preferred treatment option. The decision, however, should involve a multidisciplinary approach considering the patient's overall health status and life expectancy, with a focus on managing potential perioperative risks related to cardiovascular and oncological concerns.

Chat GPT 4.0

Answer 2024-11-05

In this case of a 74-year-old male with a complete tear of the supraspinatus tendon and other shoulder-related complications, as well as a significant history of prostate cancer with bone metastasis, atrial fibrillation, and past myocardial infarction, treatment must be considered carefully to avoid complications and prioritize symptom management. Here's an outline of possible treatment options, along with a recommendation for the preferred treatment.

Treatment Options
1. **Conservative Management**
   - *Activity modification*: Avoid activities that worsen pain and avoid lifting heavy objects with the affected arm.
   - *Physical Therapy*: Gradual, supervised physical therapy to improve range of motion and strength, especially given the limited range with exorotation and abduction.
   - *Analgesics*: Use of acetaminophen or non-opioid analgesics as first-line management for pain, as NSAIDs may carry risks given the patient's history of myocardial infarction and atrial fibrillation.
   - *Corticosteroid Injection*: Local corticosteroid injection may help reduce inflammation and pain. However, care must be taken due to the risk of exacerbating bone metastasis pain or potentially interfering with bone integrity.

2. **Surgical Repair**
   - *Arthroscopic Rotator Cuff Repair*: Surgical repair of the supraspinatus tendon tear may be indicated in younger or healthier patients. However, in this patient with a history of malignancy with bone metastases, advanced age, and limited function, surgery poses a higher risk of complications.
   - *Reverse Total Shoulder Arthroplasty (RTSA)*: This can be considered in patients with irreparable rotator cuff tears. However, the patient's medical history (especially the malignancy and the heart conditions) presents considerable surgical risks.

3. **Interventional Pain Management**
   - *Nerve Block*: An interventional procedure, such as a suprascapular nerve block, may help with pain relief in patients who cannot undergo surgery. This can provide temporary pain relief, especially if physical therapy is painful.

Preferred Treatment Plan
Given the patient's complex medical background, conservative management is the preferred initial treatment approach:

1. **Conservative Management**: A course of physical therapy focused on gentle stretching and strengthening exercises is recommended. Supervised physical therapy will help improve shoulder function while avoiding exacerbation of pain.
2. **Pain Management**: Oral analgesics, such as acetaminophen, are preferred over NSAIDs due to cardiovascular risks. If additional pain relief is necessary, a corticosteroid injection or a suprascapular nerve block can be considered, with close monitoring for any adverse effects on bone health given the history of metastasis.
3. **Follow-up and Monitoring**: Regular follow-up with both the GP and specialists (orthopedic and oncology) is essential to monitor pain, shoulder function, and the potential progression of metastasis.

Rationale
The patient's advanced age, history of cancer with bone metastases, and cardiac comorbidities make surgical options high-risk. Conservative management with careful pain

control and functional rehabilitation aligns best with the goal of improving quality of life without introducing unnecessary surgical risk.

Answer 2024-11-07

For a 74-year-old male with a complete tear of the supraspinatus tendon, preexisting conditions, and specific medication profile, treatment options should consider the patient's overall health, comorbidities, and functional goals. Here's a comprehensive approach based on current orthopedic and geriatric guidelines.

1. **Conservative Management (Preferred for Initial Treatment)**

Given the patient's advanced age, comorbidities (notably the history of prostate carcinoma with bone metastasis, myocardial infarction, and atrial fibrillation), and anticoagulant use (rivaroxaban), conservative treatment may be safer and is often the preferred approach in elderly patients, especially when surgical risks are high.

Conservative Treatment Measures:
- **Physical Therapy:** A tailored physical therapy program focusing on gentle range-of-motion exercises, progressing to strengthening exercises, to prevent stiffness and maintain shoulder function.
- **Pain Management:** Nonsteroidal anti-inflammatory drugs (NSAIDs) or acetaminophen as first-line agents for pain, provided they are compatible with the patient's current medications and renal function.
- **Steroid Injections (Considered with Caution):** Corticosteroid injections into the shoulder joint can help manage pain and inflammation. However, given the patient's history of bone metastasis, regular injections should be used cautiously, as they could potentially weaken the local musculature and tendons further.
- **Activity Modification:** The patient may be advised to modify activities that aggravate shoulder pain, focusing on exercises that do not place undue stress on the supraspinatus tendon.

Guidelines and Considerations:
- Given the increased fluid in the bursa and hematoma, initial rest and cold compresses may also help reduce inflammation.
- For patients on anticoagulants, NSAIDs should be used with caution due to bleeding risk. If pain control remains inadequate, a trial of acetaminophen is generally safer.

2. **Surgical Intervention (Considered but not Preferred)**

Surgical repair of a complete supraspinatus tear may be indicated for younger, healthy patients who wish to regain full shoulder function. However, for elderly patients with multiple comorbidities, the risks associated with surgery, anesthesia, and potential bleeding complications (given anticoagulant therapy) often outweigh the benefits.

Considerations Against Surgery:
- **Risk of Complications:** The patient's history of prostate carcinoma with bone metastasis, atrial fibrillation, and previous myocardial infarction significantly increases the risk of perioperative complications.
- **Anticoagulation Management:** The patient's use of rivaroxaban and amiodarone complicates surgical planning, as rivaroxaban increases bleeding risk. Holding or adjusting anticoagulation may expose him to thromboembolic risks, particularly due to his history of atrial fibrillation.

If Surgery is Considered (Rarely):
- If non-operative management fails and pain severely limits the quality of life, referral to an orthopedic specialist for discussion of potential surgical options (e.g., rotator cuff repair or arthroplasty) could be considered.
- A multidisciplinary team would need to manage anticoagulation carefully in the perioperative period, potentially consulting cardiology for advice on bridging therapy if surgery is pursued.

3. **Ongoing Management and Monitoring**

Given the patient's history of bone metastasis, regular monitoring for any signs of worsening musculoskeletal pain or further deterioration in the shoulder joint is essential. The general practitioner should work closely with physical therapists and potentially an orthopedic specialist to monitor shoulder function and adapt treatment as needed.

Summary
The **preferred treatment** for this patient is **conservative management** with physical therapy, pain management, and activity modification, emphasizing safety given his comorbidities and medication profile. Surgery would generally be avoided in this case due to the high perioperative risk.

Answer 2024-11-09

In treating a 74-year-old male with a complete tear of the supraspinatus tendon and a history of multiple significant medical conditions (prostate carcinoma with bone metastasis, atrial fibrillation, myocardial infarction), a tailored approach is necessary. Key factors to consider include his age, comorbidities, risk of surgery, and the impact of his current condition on quality of life.

Here are the treatment options, along with considerations for each:

1. **Conservative (Non-Surgical) Management**
- **Physical Therapy:** Given the supraspinatus tear and limited range of motion, a program focusing on shoulder stability, strengthening of remaining rotator cuff muscles, and gradual pain-free range of motion exercises can help improve function.
- **Analgesics and Anti-Inflammatory Medications:** While NSAIDs can alleviate pain and inflammation, his current medications and history of myocardial infarction make this a riskier option. Acetaminophen or topical NSAIDs may be considered to manage pain while minimizing systemic effects.
- **Corticosteroid Injection:** Although corticosteroid injections may reduce inflammation and pain, their use in patients with a history of bone metastasis and atrial fibrillation requires careful risk assessment, as they may exacerbate osteoporosis or increase bleeding risk, especially with rivaroxaban.
- **Ultrasound-Guided Injections:** Subacromial bursa injections with corticosteroids or local anesthetics can provide pain relief and improve range of motion. This approach may be cautiously considered, though the impact on tendon healing and existing bone metastasis should be evaluated.

This conservative approach is generally the preferred treatment in older adults, particularly with complex comorbidities, as it avoids surgical risks and can still improve quality of life.

2. **Surgical Repair**

- **Arthroscopic Rotator Cuff Repair:** For younger, healthier patients, surgical repair might be more strongly recommended, but in older adults, particularly with significant comorbidities, surgery comes with heightened risks.
- **Reverse Shoulder Arthroplasty (RSA):** In cases of massive rotator cuff tears with limited shoulder function, RSA may be considered. However, the invasive nature and high risk of perioperative complications (particularly due to his cardiac history and anticoagulation therapy) often make this less desirable.

Surgery is generally not preferred due to his age, cardiovascular risks, history of metastatic cancer, and the high probability of complications.

3. **Guideline-Based Preferred Treatment**
Given the patient's age, comorbidities, and lack of trauma origin, conservative management is the preferred treatment, especially with respect to guidelines on treating elderly patients with rotator cuff tears. According to the American Academy of Orthopedic Surgeons (AAOS) and European Society of Shoulder and Elbow Surgery (SECEC) guidelines:

- **Recommend conservative treatment** first for elderly patients with degenerative rotator cuff tears, especially when considering significant comorbidities.
- **Regular follow-ups** to assess pain, range of motion, and functionality, as well as adjusting treatment as needed.
- **Consider interventional options** (like corticosteroid injections) only if conservative therapy does not yield adequate pain control or functional improvement.

Given this patient's profile, conservative management with a focus on physical therapy and pain management is the most suitable approach, with surgery reserved only if conservative measures fail and the patient's functional impairment is severe.

Addendum: Case 2 Therapeutic Case 2: Sialolithiasis parotid gland

Chat GPT 3.5

Belgian 17 year old male, visits the general practitioner with a swollen jaw.
symptoms and complaints: Since yesterday pain at the right side of the jaw mostly during a meal. Today a sudden increase in pain with a clear swelling of the right jaw. With a closed jaw pain occurs only when opening the mouth and chewing food. Recent control at the dentist found no abnormalities
Physical examination: Periauricular pressure pain. Bulging of the ductus parotideus. No pain of the teeth when biting or external pressure. No fever
Technical examination: None
Medical history: 2018: greenstick fracture distal radius, 2020: frenulotomy
Medication use: None

Give the possible treatment options and the preferred treatment. Be specific and incorporate any applicable guidelines

Answer 2024-01-13

Based on the provided information, the 17-year-old Belgian male presents with a swollen jaw and pain, particularly during meals. The sudden increase in pain, along with the swelling, indicates a need for investigation and possible treatment. The physical examination reveals periauricular pressure pain and bulging of the ductus parotideus.

Possible diagnoses could include parotitis, sialadenitis, or salivary gland stones. Given the absence of fever, and considering the sudden onset and localized symptoms, viral parotitis may be a primary consideration.

Possible Treatment Options:

1. **Supportive Care:**
   - Encourage good oral hygiene.
   - Increase fluid intake.
   - Apply warm compresses to the affected area.
   - Chewing gum or sour candies may help stimulate saliva flow.

2. **Pain Management:**
   - Over-the-counter pain relievers, such as ibuprofen or acetaminophen, can be recommended for pain control.

3. **Antibiotics (if bacterial infection is suspected):**
   - If there are signs of bacterial infection, such as pus discharge or severe symptoms, antibiotics like amoxicillin or clindamycin may be considered.

4. **Sialogogues (if salivary gland stones are suspected):**
   - Sour candies or drinks can stimulate saliva production and help dislodge small stones.

5. **Referral to an Oral and Maxillofacial Surgeon:**
   - If the condition persists or worsens, a referral to an oral and maxillofacial surgeon may be necessary for further evaluation and possible drainage of an abscess.

Preferred Treatment:
Based on the information provided, the preferred initial treatment may include supportive care, pain management with over-the-counter medications, and observation. If there is a suspicion of a bacterial infection, antibiotics may be considered. However, given the absence of fever and the sudden onset of symptoms, a conservative approach with supportive care may be appropriate initially.

Follow-up:
The patient should be advised to follow up if symptoms persist or worsen. If there is no improvement within a few days, or if there are signs of systemic illness, further investigations such as imaging (ultrasound, CT scan) may be considered. Referral to a specialist, such as an oral and maxillofacial surgeon, may also be indicated for a more comprehensive evaluation and potential intervention.

It is important to note that the above recommendations are general and may vary based on the clinical judgment of the healthcare provider. Following local clinical guidelines and considering any updates or changes in medical literature is essential.

Answer 2024-02-27

Based on the symptoms and examination findings described, the likely diagnosis is parotitis, which is inflammation of the parotid gland. Parotitis can be caused by various factors such as viral or bacterial infections, obstruction of the salivary duct, or autoimmune conditions.

Possible treatment options for parotitis include:

1. Antibiotics: If the parotitis is suspected to be bacterial in origin, antibiotics such as amoxicillin/clavulanate or clindamycin may be prescribed. However, antibiotics may not be necessary if the cause is viral.

2. Pain management: Over-the-counter pain relievers such as ibuprofen or acetaminophen can help alleviate pain and discomfort.

3. Warm compress: Applying a warm compress to the swollen area can help reduce inflammation and relieve pain.

4. Salivary gland massage: Massaging the affected gland may help promote saliva flow and alleviate symptoms.

5. Hydration: Drinking plenty of fluids can help keep the saliva flowing and prevent dehydration, which can worsen symptoms.

6. Sialogogues: Chewing sugar-free gum or sucking on sour candies can stimulate saliva production and help clear the ducts.

Preferred treatment:

Given the absence of fever and the lack of indication for bacterial infection based on the clinical presentation, the preferred treatment would initially focus on conservative measures

such as pain management, warm compress, salivary gland massage, hydration, and sialogogues. Antibiotics may not be necessary unless there is clinical suspicion or confirmation of bacterial infection. However, close monitoring of symptoms is essential, and if there is no improvement or worsening of symptoms despite conservative measures, further evaluation and consideration of antibiotic therapy may be warranted. Additionally, referral to an otolaryngologist may be necessary for further assessment and management, especially if there are recurrent episodes of parotitis or if complications develop.

Answer 2024-04-30

Based on the symptoms and examination findings described for a 17-year-old Belgian male presenting with a swollen jaw and pain, the most likely diagnosis could be acute sialadenitis, which is inflammation of a salivary gland, commonly the parotid gland in this case. Here are the possible treatment options and the preferred course of action:

1. **Conservative Management:**
   - **Hydration:** Encourage adequate hydration to help stimulate saliva flow and prevent dehydration, which can contribute to salivary gland issues.
   - **Analgesics:** Use over-the-counter pain relievers such as acetaminophen or ibuprofen to manage pain and inflammation.
   - **Warm Compresses:** Applying warm compresses to the affected area can help reduce pain and swelling.

2. **Antibiotics:**
   - If there are signs of bacterial infection or worsening symptoms (e.g., fever, increasing swelling), antibiotics may be indicated. Common choices include amoxicillin-clavulanate or clindamycin, targeting common pathogens associated with sialadenitis.

3. **Saliva Stimulation:**
   - Sour candies or sugar-free gum can stimulate saliva production and help clear the salivary ducts.

4. **Sialogogues:**
   - In severe cases or for persistent symptoms, medications like pilocarpine may be used to stimulate saliva production.

5. **Surgical Intervention:**
   - If there is evidence of an abscess or if conservative measures fail, drainage of the abscess may be necessary. This can be performed under local anesthesia.

Preferred Treatment:
The preferred initial treatment for acute sialadenitis in this case would likely involve conservative management:
- **Hydration:** Encourage the patient to drink plenty of fluids.
- **Analgesics:** Prescribe or recommend over-the-counter pain relief (e.g., acetaminophen).
- **Warm Compresses:** Instruct the patient on the use of warm compresses to the affected area.

If symptoms worsen or fail to improve with conservative measures, a follow-up visit would be needed for reevaluation and consideration of antibiotic therapy. Referral to an otolaryngologist may be required if there is no improvement or if there is concern for abscess formation. This approach aligns with general medical guidelines for managing acute sialadenitis in young patients without severe systemic symptoms or complications.

Chat GPT 4.0

Answer 2024-11-05

Based on the presentation, this patient likely has acute sialadenitis, which is an inflammation of the salivary gland, typically the parotid gland in cases with periauricular swelling. The main features suggesting this are the periauricular pain, bulging of the ductus parotideus, and pain associated with eating and jaw movement.

Possible Treatment Options:

1. **Hydration and Sialogogues**:
   - Encourage the patient to stay well-hydrated, as this can help thin the saliva, reducing the risk of duct obstruction.
   - Sialogogues (like sour candies or lemon drops) stimulate saliva production, potentially helping clear any ductal blockage.

2. **Warm Compresses and Massage**:
   - Applying warm compresses over the swollen area can increase blood flow and may help reduce swelling and pain.
   - Gentle massage of the gland in a direction that encourages saliva flow (from the gland toward the duct opening) can also help alleviate blockage.

3. **Analgesics**:
   - Non-steroidal anti-inflammatory drugs (NSAIDs) can relieve pain and inflammation. Over-the-counter options like ibuprofen or acetaminophen may be recommended.

4. **Antibiotics (if infection suspected)**:
   - If bacterial infection is suspected (indicated by the rapid onset of pain and swelling), empirical antibiotic treatment may be warranted. A common regimen includes **amoxicillin-clavulanate** to cover the typical pathogens involved in sialadenitis, such as *Staphylococcus aureus* or oral flora. In case of penicillin allergy, **clindamycin** is an alternative.
   - Antibiotics are typically prescribed for 7-10 days.

5. **Follow-up**:
   - Close follow-up is essential to monitor symptom progression and response to treatment.
   - If symptoms do not improve within 2-3 days, imaging such as an ultrasound may be warranted to evaluate for abscess formation or other causes of obstruction, like stones (sialolithiasis).

Preferred Treatment

Given the presentation, start with conservative treatment with hydration, sialogogues, warm compresses, and NSAIDs. If the swelling and pain persist or worsen, or if signs of systemic infection (e.g., fever) develop, initiate antibiotic therapy, starting with **amoxicillin-clavulanate** as the preferred first-line option.

Answer 2024-11-07

The symptoms and findings are suggestive of **acute parotitis**, likely due to an obstruction or infection of the parotid gland. Here’s a structured approach for treatment and management options:

1. **Supportive Care and Symptomatic Management:**
- **Hydration:** Encourage adequate fluid intake to stimulate saliva production, which helps with drainage of the parotid gland.
- **Warm Compresses:** Apply warm compresses to the swollen area to promote drainage.
- **Sialogogues:** Encourage the use of sour candies or lemon drops to stimulate saliva flow and help clear the duct.
- **Massage of the Gland:** Gentle massage of the affected parotid gland from posterior to anterior may help clear any blockages.

2. **Pharmacological Management:**
- **Antibiotics:** Given the swelling and pain, there is a risk of bacterial infection, particularly from *Staphylococcus aureus* or *Streptococcus* species. Empirical antibiotic therapy is recommended, especially if the patient does not show improvement with supportive care alone.
  - **Recommended Antibiotic Regimen:** Amoxicillin-clavulanic acid is often used as the first line. In patients allergic to penicillin, clindamycin may be a suitable alternative. The course should typically be 7–10 days.
- **Pain Management:** Over-the-counter analgesics like ibuprofen or paracetamol can help manage pain and reduce inflammation.

3. **Follow-Up and Referral:**
- Monitor symptoms for improvement over the next 48–72 hours. If the swelling, pain, or symptoms worsen or do not improve, consider referral to an otolaryngologist for further assessment and possibly imaging to exclude other causes, such as stones or masses in the gland.

Preferred Treatment:
- **Supportive care** (hydration, warm compresses, sialogogues, and gland massage).
- **Antibiotic therapy** with amoxicillin-clavulanic acid (7–10 days).
- **Pain management** with nonsteroidal anti-inflammatory drugs (NSAIDs) or paracetamol.

Additional Considerations:
- If the condition does not improve or recurs, imaging (such as ultrasound) may be considered to check for any underlying ductal stones (sialolithiasis) or other obstructive pathology.

Answer 2024-11-09

The patient's symptoms, including pain and swelling around the jaw, particularly during meals, along with periauricular pain and bulging of the ductus parotideus, suggest **sialadenitis** or **sialolithiasis** (salivary gland infection or stone in the parotid duct). Given the absence of fever, this presentation likely points to an obstruction of the parotid duct, potentially due to a salivary stone, rather than an infectious etiology.

Possible Treatment Options:

1. **Conservative Management:**
   - **Hydration and Massage**: Increasing fluid intake and massaging the affected gland can help flush out the obstruction, if present.
   - **Sialogogues**: Sour candies or lemon drops stimulate saliva production, potentially helping to dislodge a stone.
   - **Warm Compresses**: Applying warmth over the swollen area may alleviate discomfort and improve drainage.
   - **Pain Management**: Over-the-counter analgesics (e.g., ibuprofen or acetaminophen) can manage pain if needed.

2. **Antibiotics** (only if infection is suspected or signs of fever develop):
   - If symptoms worsen or if signs of infection arise, an empirical antibiotic covering common pathogens like **Staphylococcus aureus** and **Streptococcus species** (e.g., amoxicillin-clavulanate or clindamycin in case of allergy) may be initiated. However, antibiotics are generally unnecessary without signs of systemic infection or fever.

3. **Further Diagnostic Evaluation** (if conservative management fails):
   - If symptoms persist or worsen despite initial conservative measures, **ultrasonography** or **non-contrast CT scan** of the parotid gland can identify stones or other obstructive causes.

4. **Surgical Intervention** (if indicated):
   - In cases of recurrent or unresolving sialolithiasis, ductal stone extraction may be necessary, typically performed by an otolaryngologist.

Preferred Treatment:

The initial preferred approach would be **conservative management** without antibiotics, as the patient lacks systemic signs of infection (such as fever). Encouraging hydration, use of sialogogues, warm compresses, and analgesia is recommended. If no improvement is noted in a few days, further imaging may be warranted to confirm or exclude a stone or other obstruction.

Follow-Up:

A follow-up appointment within a few days is advisable to assess improvement.

Addendum: Case 3 Therapeutic Case 3: Toxoplasmosis infection in pregnancy

Chat GPT 3.5

Belgian 33 year old female, visits the general practitioner with a positive pregnancy test.
symptoms and complaints: positive pregnancy test 8 weeks after last menstruation. No symptoms
Physical examination: Weight 65kg. Blood pressure 110/70. Normal abdomen
Technical examination: HCG: 13941 U/L. Toxoplasmosis IgG negatif, Toxoplasmosis IgM positif
Medical history: 1 pregnancy with normal delivery
Medication use: folic acid

Give the possible treatment options and the preferred treatment. Be specific and incorporate any applicable guidelines

Answer 2024-01-13

Based on the information provided, it appears that the 33-year-old Belgian female is 8 weeks pregnant and has a positive pregnancy test. The HCG level is 13941 U/L, and there is a positive Toxoplasmosis IgM result.

Given this information, there are a few considerations to take into account, especially with the positive Toxoplasmosis IgM result, which suggests a recent infection. Toxoplasmosis is an infection caused by the parasite Toxoplasma gondii, and it can be harmful to the developing fetus if the infection occurs during pregnancy.

Possible treatment options and considerations:

1. **Toxoplasmosis Treatment:**
   - Due to the positive Toxoplasmosis IgM result, treatment for toxoplasmosis may be necessary.
   - Preferred treatment options may include a combination of pyrimethamine, sulfadiazine, and folinic acid (leucovorin).
   - The decision to treat toxoplasmosis during pregnancy should be made in consultation with an infectious disease specialist or a healthcare provider experienced in managing maternal-fetal infections.

2. **Folic Acid Supplementation:**
   - It's positive that the patient is already taking folic acid, as this is important for preventing neural tube defects in the developing fetus. The standard recommendation is 400 micrograms of folic acid daily, and it is usually recommended to continue this supplementation throughout the first trimester.

3. **Prenatal Care:**

- The patient should continue with routine prenatal care, which includes regular check-ups, ultrasounds, and monitoring of maternal and fetal well-being.

4. **Monitoring of HCG Levels:**
   - Regular monitoring of HCG levels may be necessary to ensure appropriate progression of the pregnancy. A healthcare provider will assess the trend and evaluate if further investigations or interventions are needed.

5. **Review of Medications:**
   - It's important to review the current medications, including folic acid, and make any necessary adjustments based on the evolving needs of the pregnancy. Some medications may need to be adjusted or discontinued, depending on their safety during pregnancy.

It's crucial for the patient to have open communication with her healthcare provider to discuss the test results, potential risks, and the recommended course of action. Additionally, local or national guidelines may provide specific recommendations for the management of toxoplasmosis during pregnancy, and these should be followed for optimal care.

Answer 2024-02-27

Given the patient's presentation and test results, it appears she is currently asymptomatic and in the early stages of pregnancy. The positive pregnancy test along with the absence of symptoms suggests a relatively uncomplicated pregnancy at this stage.

However, the positive Toxoplasmosis IgM test result is notable and should be addressed. Toxoplasmosis is an infection caused by the parasite Toxoplasma gondii, which can be harmful to the fetus if contracted during pregnancy, particularly if acquired during the first trimester.

Treatment options and considerations:

1. **Observation and monitoring**: In cases where the patient is asymptomatic and the infection is detected early, some guidelines recommend close monitoring of the patient and the fetus without immediate treatment. This involves regular follow-ups and testing to monitor the progression of the infection and any potential impact on the pregnancy.

2. **Pyrimethamine and sulfadiazine**: These are commonly used medications to treat toxoplasmosis in pregnancy. However, their use is associated with potential risks to the fetus, particularly in the first trimester. The decision to use these medications should be carefully weighed against the potential risks and benefits, and it is typically reserved for cases where there is evidence of fetal infection or severe maternal disease.

3. **Spiramycin**: Spiramycin is an antibiotic that is often used to treat toxoplasmosis during pregnancy. It is believed to be safer than pyrimethamine and sulfadiazine, particularly in the early stages of pregnancy, as it has a lower risk of crossing the placenta. However, it is primarily used to prevent vertical transmission to the fetus rather than treat maternal infection.

Preferred treatment:

Given the patient's early stage of pregnancy, asymptomatic presentation, and positive Toxoplasmosis IgM result, the preferred treatment option would likely be observation and monitoring with close follow-up. This approach aligns with guidelines that suggest reserving

treatment with pyrimethamine and sulfadiazine for cases where there is evidence of fetal infection or severe maternal disease. Additionally, considering the potential risks associated with medication use in pregnancy, particularly in the first trimester, the conservative approach of observation and monitoring would be prudent in this case.

The patient should be counseled regarding measures to minimize the risk of toxoplasmosis infection during pregnancy, such as avoiding raw or undercooked meat, washing fruits and vegetables thoroughly, and avoiding contact with cat feces. Regular follow-up appointments should be scheduled to monitor the progression of the infection and assess any potential impact on the pregnancy. If there are any concerning developments or if fetal infection is suspected, treatment options can be reassessed and adjusted accordingly in consultation with a maternal-fetal medicine specialist.

Answer 2024-04-30

Given the patient's presentation and laboratory findings, the positive Toxoplasmosis IgM test suggests recent infection with Toxoplasma gondii, a parasite that can be harmful during pregnancy. Here are the possible treatment options and the preferred approach based on guidelines:

1. **Treatment Options**:
   - **Spiramycin**: This antibiotic is commonly used to treat maternal toxoplasmosis during pregnancy. Spiramycin can help prevent the transmission of the parasite from the mother to the fetus.
   - **Pyrimethamine and Sulfadiazine (with Leucovorin)**: In cases where fetal infection is confirmed or suspected, a more aggressive treatment regimen with pyrimethamine and sulfadiazine, along with folinic acid (Leucovorin), may be necessary to treat toxoplasmosis.

2. **Preferred Treatment**:
   - **Spiramycin**: The European guideline on the management of Toxoplasma gondii infection during pregnancy recommends starting with spiramycin when a pregnant woman is diagnosed with acute toxoplasmosis, particularly during the first trimester or early in the second trimester. Spiramycin has the advantage of being safer during pregnancy and is effective in reducing the risk of vertical transmission to the fetus. It is generally administered until the diagnosis is confirmed and further evaluation is conducted to assess the risk to the fetus.
   - **Follow-up Testing**: The patient should be closely monitored with regular check-ups and follow-up laboratory tests to evaluate the effectiveness of treatment and to assess fetal health. This may include serial ultrasounds and additional testing for the presence of the parasite in amniotic fluid or fetal blood if necessary.

3. **Additional Recommendations**:
   - **Educational Counseling**: The patient should receive counseling regarding the potential risks associated with toxoplasmosis during pregnancy, including the importance of hygiene practices to prevent exposure to the parasite.
   - **Continued Folic Acid Supplementation**: The patient should continue taking folic acid as recommended, as it is important for preventing neural tube defects and supporting fetal development.

It's crucial for the patient to discuss these findings and treatment options with her healthcare provider to ensure appropriate management and care during pregnancy. The specific treatment plan may vary based on individual circumstances and additional diagnostic evaluations.

Chat GPT 4.0

Answer 2024-11-05

In this case, the main concerns revolve around the positive Toxoplasma IgM, which indicates a potential acute toxoplasmosis infection. Toxoplasmosis can pose a risk to the fetus, especially if contracted during early pregnancy. Here are the key steps and possible treatment options based on the information provided:

1. **Confirming Acute Toxoplasmosis Infection**
- **Further Testing:** Given the positive IgM and negative IgG, it is important to confirm the presence of acute infection. False-positive IgM results can sometimes occur, so a follow-up test is generally recommended. This might include:
    - A repeat IgG and IgM test to confirm seroconversion.
    - A Toxoplasma PCR test on amniotic fluid (usually recommended if fetal infection is suspected and typically performed after 18 weeks of gestation).
- **Ultrasound Monitoring:** Regular ultrasounds are advised to assess fetal development and detect any potential anomalies associated with toxoplasmosis.

2. **Treatment Options if Acute Toxoplasmosis is Confirmed**
- **Early Pregnancy (First Trimester) Treatment:** If the infection is confirmed during the first trimester, **spiramycin** is generally the preferred treatment. Spiramycin does not cross the placenta as readily as other medications and is used to reduce the risk of transmission to the fetus.
    - **Dosage**: Spiramycin 1 g (3 million IU) three times daily.
    - **Duration**: Until the end of pregnancy if the infection is not transmitted or until a later trimester when an alternative medication is considered if fetal infection is confirmed.
- **If Fetal Infection is Suspected (Second and Third Trimester):** If PCR testing on amniotic fluid confirms fetal infection, a combination of **pyrimethamine, sulfadiazine,** and **folinic acid** may be used instead.
    - **Dosage**: This regimen should be closely monitored and adjusted by a specialist.
    - **Duration**: Treatment usually continues throughout the remainder of the pregnancy to mitigate the risk of fetal complications.

3. **Other Management Considerations**
- **Folic Acid Continuation:** Continue folic acid supplementation, as it is standard during pregnancy.
- **Informed Counseling:** Counseling is essential to explain the risks associated with toxoplasmosis, the implications of maternal infection, and the steps in monitoring and treatment. This includes dietary and hygiene precautions to prevent further toxoplasmosis exposure (e.g., avoiding undercooked meat, unwashed vegetables, and contact with cat litter).

4. **Guideline Considerations**
- European and international guidelines suggest starting spiramycin in cases where acute toxoplasmosis infection is suspected or confirmed in the mother, especially early in pregnancy, to reduce the risk of fetal transmission. Guidelines also recommend amniocentesis with PCR if fetal infection is suspected, typically after the 18th week, as the procedure carries risks if done earlier.

Preferred Treatment:

- **Start Spiramycin 1 g three times daily** as the preferred treatment if the acute infection is confirmed. This is to prevent fetal transmission until further tests can better assess fetal infection status.
- If fetal infection is later confirmed, a transition to **pyrimethamine, sulfadiazine, and folinic acid** can be considered, typically guided by a specialist in maternal-fetal medicine.

Answer 2024-11-07

The patient is an 8-week pregnant woman who tested positive for Toxoplasmosis IgM and negative for IgG, indicating a potential recent infection with *Toxoplasma gondii*. Managing toxoplasmosis in pregnancy is crucial as the infection can lead to congenital toxoplasmosis, potentially causing severe complications for the fetus, especially when contracted in the first trimester. Here are the treatment options and guidelines.

Treatment Options and Guidelines:

1. **Confirm the Diagnosis**
   - Although the patient has a positive Toxoplasmosis IgM and negative IgG, these tests alone may not confirm a recent infection. The IgM result could be a false positive, so further confirmatory tests, such as an IgG avidity test, should be conducted if available. Low-avidity IgG may indicate recent infection, while high-avidity IgG generally rules out infection within the past 4-5 months.
   - Consult with a specialist in infectious diseases, obstetrics, or maternal-fetal medicine for guidance on further testing.

2. **Initiate Treatment if Infection is Confirmed**
   - If further testing confirms recent infection, treatment should begin to reduce the risk of transmission to the fetus.

3. **Medication Options by Trimester**
   Treatment options are trimester-specific according to current guidelines, with the aim to reduce fetal transmission and manage infection.

   - **First Trimester (0-13 Weeks)**
     - If confirmed infection occurs in the first trimester, **spiramycin** is the preferred treatment. Spiramycin does not cross the placenta well but concentrates in the placenta to help prevent transmission to the fetus.
     - **Dosage:** Spiramycin 3 million IU orally every 8 hours.
     - **Duration:** Continue treatment until delivery or transition to other medications based on infection status and fetal testing.

   - **Second and Third Trimesters (after fetal infection confirmation)**
     - If fetal infection is confirmed (via amniocentesis and PCR testing for Toxoplasma DNA in the amniotic fluid), **pyrimethamine, sulfadiazine, and folinic acid** are typically given.
     - Pyrimethamine and sulfadiazine are effective against fetal infection but are generally avoided in the first trimester due to teratogenicity risks.
     - **Dosage:**
       - Pyrimethamine: Initial dose 50 mg daily for two days, then 25 mg daily.
       - Sulfadiazine: 1 g every 12 hours.
       - Folinic acid: 10-20 mg every other day to counteract pyrimethamine's effects on folate metabolism.
     - **Duration:** Continue until delivery, with treatment cycles as advised by specialists.

4. **Monitoring and Follow-Up**
   - Close monitoring throughout pregnancy, including regular ultrasounds to assess fetal growth and development.
   - Consider repeat serologic testing to monitor IgM and IgG levels.
   - Amniocentesis is usually performed after 18 weeks if fetal infection is suspected, as per guidelines.

5. **Counseling and Education**
   - Educate the patient on ways to prevent further exposure to *Toxoplasma* (e.g., avoiding raw or undercooked meat, washing vegetables, and avoiding contact with cat litter).
   - Provide emotional support and resources, as toxoplasmosis can cause significant stress during pregnancy.

Preferred Treatment:
Given the patient's gestational age (8 weeks), the preferred approach would involve:
- Confirming the infection through additional testing to avoid unnecessary treatment.
- If confirmed, initiate **spiramycin therapy** to reduce the risk of vertical transmission, as recommended in the first trimester.

This approach aligns with evidence-based guidelines and minimizes fetal risk. The patient should be referred to a maternal-fetal medicine specialist for optimal management and follow-up.

Answer 2024-11-09

For a pregnant patient with a positive Toxoplasmosis IgM and negative IgG result, it is essential to consider the risks associated with Toxoplasma gondii infection during pregnancy, as it can cause congenital toxoplasmosis, which can be harmful to the fetus.

Diagnostic Follow-Up
1. **Confirm Diagnosis**: A positive Toxoplasmosis IgM with a negative IgG can sometimes indicate a false positive. Further testing, such as an IgG avidity test, may be recommended to help determine if this is a recent infection. If the avidity is low, this indicates a recent infection and poses a risk to the fetus.

2. **Ultrasound Monitoring**: Regular ultrasound monitoring can help detect any potential fetal complications related to congenital toxoplasmosis, such as hydrocephalus, intracranial calcifications, or growth restriction.

Treatment Options
If a recent toxoplasmosis infection is confirmed, treatment should commence to reduce the risk of vertical transmission to the fetus.

1. **Spiramycin Therapy**:
   - **Indication**: Spiramycin is the preferred treatment for maternal toxoplasmosis without confirmed fetal infection. Spiramycin does not cross the placenta effectively, making it suitable for maternal infection by reducing the likelihood of transmission to the fetus.
   - **Dosage**: Typically, 1 gram of spiramycin every 8 hours (3 grams daily) until delivery.
   - **Monitoring**: Regular blood tests to monitor spiramycin levels and adherence to dosage guidelines.

2. **Pyrimethamine-Sulfadiazine with Folinic Acid**:

- **Indication**: If fetal infection is suspected or confirmed (through amniotic fluid PCR or ultrasound findings), then treatment with pyrimethamine and sulfadiazine is preferred, as this combination crosses the placenta and treats fetal infection.
- **Dosage**: This regimen typically starts in the second trimester due to potential teratogenic effects in the first trimester. Folinic acid should accompany this treatment to reduce bone marrow toxicity.

Preferred Treatment Approach Based on Current Case
Since there is no confirmation of fetal infection at this stage, **spiramycin** would be the preferred treatment due to its safety profile and efficacy in reducing maternal-fetal transmission.

Regular follow-up with ultrasound and additional testing for fetal infection will guide if any changes in treatment are necessary as the pregnancy progresses.

Addendum: Case 4 Therapeutic Case 4: Contraception

Chat GPT 3.5

A Belgian 17 year old female, visits the general practitioner and wants to start with birth control.
symptoms and complaints: Wants to start birth control. Not really clear why she wants to start. Not sexually active. regular menses. No real subjective bother. Non smoker, no deep venous thrombosis or lung embolism in her history. Prefers a pill form of birth control. Fear of needles.
Physical examination:
Technical examination:
Medical history: Epilepsy, slight psychomotor development disorder
Medication use: levetiracetam 2*750 mg

Give the possible treatment options and the preferred treatment. Be specific and incorporate any applicable guidelines

Answer 2024-01-13

Given the information provided, it's important to consider the patient's medical history, preferences, and any potential interactions with current medications. In this case, the patient is a 17-year-old Belgian female with epilepsy who wants to start birth control. Here are some possible treatment options:

1. **Combined Oral Contraceptives (COCs):**
   - Pros: Effective in preventing pregnancy, regulates menstrual cycles, and may reduce menstrual cramps.
   - Cons: Requires daily administration, potential side effects (e.g., nausea, breast tenderness).
   - Consideration: COCs may interact with certain antiepileptic drugs, potentially reducing their effectiveness. Therefore, it's crucial to discuss this with the patient's neurologist.

2. **Progestin-Only Pills (POPs):**
   - Pros: Suitable for women who can't take estrogen-containing contraceptives, may be taken by women with epilepsy.
   - Cons: Must be taken at the same time every day, may cause irregular bleeding.
   - Consideration: POPs are less likely to interact with antiepileptic drugs compared to COCs, making them a potential option.

3. **Contraceptive Patch:**
   - Pros: Weekly application, no daily pill administration.
   - Cons: May cause skin irritation, similar side effects to COCs.
   - Consideration: The patch contains estrogen and progestin, so potential interactions with antiepileptic drugs should be considered.

4. **Contraceptive Ring:**
   - Pros: Monthly insertion, no daily pill administration.
   - Cons: May cause vaginal irritation, similar side effects to COCs.

- Consideration: Like the patch, the ring contains estrogen and progestin, so potential interactions with antiepileptic drugs should be considered.

5. **Intrauterine Device (IUD):**
- Pros: Long-term contraception, highly effective.
- Cons: Insertion discomfort, irregular bleeding, possible expulsion.
- Consideration: IUDs are generally suitable for women with epilepsy and may not have significant drug interactions.

Considering the patient's preference for a pill form of birth control and fear of needles, a progestin-only pill (POP) or possibly a low-dose combined oral contraceptive (COC) with careful monitoring for interactions with antiepileptic drugs could be considered.

It's crucial to involve the neurologist in the decision-making process, as some antiepileptic drugs can interact with hormonal contraceptives, potentially affecting their efficacy. Additionally, the patient should be informed about the importance of consistent and timely pill-taking, and the potential side effects of the chosen contraceptive method. Regular follow-ups with both the general practitioner and neurologist are recommended to monitor for any adverse effects or changes in the patient's health status.

Answer 2024-02-27

Given the patient's age, medical history, and preference for a pill form of birth control, along with her lack of clear indication for contraceptive use, it's important to consider the options carefully. Here are the possible treatment options along with the preferred treatment:

1. Combined Oral Contraceptive Pills (COCPs):
- These contain both estrogen and progestin.
- Guidelines typically recommend COCPs as a first-line option for young, healthy individuals without contraindications.
- However, due to the patient's epilepsy, there may be concerns about potential interactions with her antiepileptic medication (levetiracetam).
- COCPs may also carry a slightly increased risk of venous thromboembolism (VTE), although this risk is generally low in young, healthy non-smokers.

2. Progestin-Only Pills (POPs):
- Also known as the "mini-pill," POPs contain only progestin.
- They are often considered a safer option for individuals with contraindications to estrogen-containing contraceptives, such as those with a history of VTE or migraine with aura.
- There are fewer drug interactions with antiepileptic medications compared to COCPs.
- However, POPs require strict adherence to a specific dosing schedule for effectiveness, which may be challenging for some patients.

3. Long-Acting Reversible Contraceptives (LARCs):
- Options such as the contraceptive implant (etonogestrel implant) or intrauterine devices (IUDs) provide highly effective contraception with minimal user effort once inserted.
- LARCs do not contain estrogen and are generally well-tolerated by most individuals.
- They may be particularly suitable for patients with epilepsy, as they do not rely on oral ingestion and are not affected by enzyme-inducing antiepileptic drugs.

Preferred Treatment:

Considering the patient's epilepsy, slight psychomotor development disorder, and preference for a pill form of birth control, as well as her lack of clear indication for contraceptive use beyond preventing pregnancy, the preferred treatment option may be Progestin-Only Pills (POPs).

These pills are less likely to interact with her antiepileptic medication and may offer a lower risk of venous thromboembolism compared to combined oral contraceptives. Additionally, the patient's fear of needles and preference for a pill form make POPs a suitable choice. However, it's important to counsel the patient on the need for strict adherence to the dosing schedule for POPs to maintain effectiveness.

Answer 2024-04-30

For a 17-year-old Belgian female who is seeking birth control but is not sexually active and has a fear of needles, the following treatment options and considerations can be explored:

1. **Birth Control Pills**: Given her preference for a pill form of birth control and no contraindications, combined oral contraceptive pills (COCs) would be a suitable option. COCs contain synthetic versions of estrogen and progesterone, which prevent ovulation and thicken cervical mucus, reducing the chance of pregnancy. It's important to note that the patient is not sexually active, so birth control pills would be primarily used for contraception rather than cycle regulation.

2. **Progestin-Only Pill (Mini-Pill)**: Since the patient has epilepsy and is taking levetiracetam, it's crucial to consider potential drug interactions. Levetiracetam can decrease the effectiveness of hormonal contraceptives, including COCs, due to its induction of hepatic enzymes. Therefore, a progestin-only pill (POP) might be a safer alternative because it is less affected by enzyme-inducing medications like levetiracetam.

3. **Contraceptive Implant or Intrauterine Device (IUD)**: Although the patient prefers a pill form and has a fear of needles, other long-acting reversible contraceptive (LARC) options like the contraceptive implant (Nexplanon) or hormonal IUD could be discussed. These methods are highly effective and do not require daily adherence.

Given the patient's preferences and medical history, the preferred treatment would likely be a progestin-only pill (POP). POPs are taken daily without a pill-free interval, which may be more manageable for the patient and less affected by her epilepsy medication.

It's important for the general practitioner to discuss these options thoroughly with the patient, taking into account her medical history, concerns, and preferences. Additionally, counseling on the importance of consistent and correct pill use, as well as potential drug interactions with levetiracetam, should be provided. Referral to a gynecologist may also be considered for further evaluation and tailored contraceptive advice.

Chat GPT 4.0

Answer 2024-11-05

Given this young woman’s medical history and her expressed preferences, there are a few contraceptive options to consider, especially in light of her epilepsy, existing medication

(levetiracetam), and fear of needles. Here is an overview of the potential treatment options, alongside a preferred treatment plan based on guidelines.

1. **Considerations with Epilepsy and Levetiracetam**
- **Drug interactions**: Certain contraceptives can interact with antiepileptic drugs, potentially lowering the effectiveness of birth control or reducing seizure control. However, **levetiracetam** is not known to interact significantly with hormonal contraceptives, which broadens the available options.
- **Type of contraception**: Given her epilepsy and preference for an oral contraceptive, a **combined oral contraceptive (COC)** or **progestin-only pill (POP)** could be suitable options.

2. **Oral Contraceptive Options**
- **Combined Oral Contraceptive Pill (COC)**:
    - Contains both estrogen and progestin, typically taken daily.
    - COCs are often preferred if there's no contraindication and the patient prefers daily oral medication.
    - However, guidelines recommend caution with estrogen-containing contraceptives in women with a history of epilepsy, as some may increase the risk of seizure threshold alterations. Estrogen may theoretically increase seizure frequency in some individuals, although this effect is more common with certain types of epilepsy.
    - Still, as she's on levetiracetam and without seizure-related COC contraindications, a low-dose COC could be a viable option.

- **Progestin-Only Pill (POP)**:
    - Contains only progestin, making it a good choice if avoiding estrogen is a priority.
    - POPs must be taken at the same time daily, which may be a drawback if adherence could be an issue.
    - However, POPs are generally safe and effective, with no significant seizure-related risks.

3. **Non-Oral Options**
- **Injection (e.g., Depot medroxyprogesterone acetate - DMPA)** or **implant**: Although these are effective, she has a fear of needles, making them less appropriate.
- **Intrauterine devices (IUDs)**: While hormonal and non-hormonal IUDs are highly effective, insertion requires a clinical procedure and may also be unacceptable to her, given her preference for pills.

4. **Preferred Treatment Recommendation**
- **Low-Dose Combined Oral Contraceptive Pill**:
    - Since she prefers a pill form, does not have contraindications for estrogen, and there are no noted interactions with levetiracetam, a low-dose combined oral contraceptive (COC) is a good choice.
    - A pill containing **30–35 µg of ethinyl estradiol** combined with **a second-generation progestin** (e.g., levonorgestrel) would be ideal, balancing effective contraception with minimized hormonal side effects.
- **Alternative Option**: If she prefers to avoid estrogen due to personal preference or theoretical seizure concerns, a **progestin-only pill (POP)** could be prescribed.

Follow-Up and Monitoring
- Schedule a follow-up visit within 1-3 months to monitor for any side effects, especially mood changes or altered seizure control, although these are unlikely with levetiracetam.
- Reinforce the importance of adherence, particularly for POPs.

- Monitor any changes in seizure activity, although significant effects on her epilepsy are unlikely with either choice.

Summary:
The preferred treatment is a **low-dose combined oral contraceptive pill (COC)** containing 30–35 µg of ethinyl estradiol and a second-generation progestin, given the lack of contraindications and her expressed preference.

Answer 2024-11-07

In this case, the patient is a 17-year-old female with epilepsy, managed with levetiracetam, and she is interested in starting oral contraceptives. Below are the treatment options, along with a recommended approach based on her history and preference.

1. **Assessment and Important Considerations**

- **Epilepsy and Medication Interaction**: Levetiracetam is generally not known to interfere with most oral contraceptives. However, certain antiepileptic drugs (AEDs) like enzyme-inducing AEDs can reduce the effectiveness of hormonal contraceptives. Since levetiracetam is non-enzyme-inducing, it does not have this issue, but this factor is essential to confirm in epilepsy patients on other AEDs.
- **Preference for Pills**: She has a clear preference for oral contraceptive pills due to a fear of needles and desire for a non-invasive method.
- **Non-Smoker with No Thromboembolic History**: This allows for a broader range of contraceptive options, as she has no thromboembolic risk factors and is not a smoker.
- **Regular Menses and No Subjective Symptoms**: This suggests she doesn't require hormonal manipulation for cycle irregularities or related symptoms, so a low-dose, monophasic contraceptive pill would be suitable.

2. **Possible Treatment Options**

a. **Combined Oral Contraceptive Pills (COCs)**: A low-dose, estrogen-progestin combined pill is typically the first-line option for young women who want oral contraceptives and have no contraindications.

- **Pros**: Effective in preventing pregnancy, may help regulate menstrual cycles and reduce dysmenorrhea, generally well tolerated.
- **Cons**: Increased risk of thromboembolic events, although low in non-smokers and in those without a family history of clotting disorders.

b. **Progestin-Only Pills (POPs)**: Also known as the "mini-pill," this is an option for patients who may want to avoid estrogen, though it's typically recommended when estrogen is contraindicated.

- **Pros**: No estrogen, hence safer for individuals with contraindications for estrogen (not applicable here).
- **Cons**: Requires strict adherence (daily intake at the same time).

c. **Other Hormonal Options (e.g., Long-Acting Injectable, Implants)**: Not recommended in this case due to her fear of needles and desire to avoid invasive methods.

3. **Preferred Treatment Option**

Given her clinical history, a **low-dose combined oral contraceptive pill (COC)** is the preferred option, specifically with a low estrogen component (usually ≤ 30 mcg of ethinyl estradiol) to minimize risks. A monophasic pill (same dose of hormones each day) is often better tolerated, especially in younger patients. Options such as a 20 mcg ethinyl estradiol and levonorgestrel pill would be a good start, as levonorgestrel is well tolerated with fewer side effects.

Guideline Consideration: Many guidelines recommend low-dose combined oral contraceptives for young, healthy individuals without risk factors for thromboembolic events, especially when contraception is started for non-contraceptive benefits.

Answer 2024-11-09

For a 17-year-old female with epilepsy, regular menses, and no history of venous thromboembolism, the most suitable birth control options need to take into account her preference for oral contraceptives, her history of epilepsy, and her current medication (levetiracetam). The goal is to choose a safe, effective, and compatible contraceptive method that does not interfere with her antiepileptic medication or her condition.

Considerations for Contraceptive Choice:

1. **Drug Interactions with Levetiracetam**: Some hormonal contraceptives, especially certain combined oral contraceptives (COCs) with estrogen and progestin, can interact with antiepileptic drugs (AEDs). Levetiracetam, however, does not significantly interact with most contraceptives, but vigilance is still required.

2. **Non-contraceptive Benefits of Hormonal Contraceptives**: Since she is not sexually active, additional benefits such as menstrual cycle regulation and management of menstrual symptoms might be considered for choosing a hormonal contraceptive.

3. **Preference for Pill Form and Aversion to Needles**: Pills align well with her preference for non-invasive options, and her needle aversion rules out injectable methods like Depo-Provera.

4. **History of Epilepsy and Potential Side Effects**: Some progestin-only contraceptives may slightly lower the seizure threshold in some individuals, which needs consideration.

Potential Treatment Options:

1. **Combined Oral Contraceptive Pill (COC)**:
   - **Advantages**: COCs with both estrogen and progestin are effective and commonly used. They can also provide additional menstrual cycle regulation.
   - **Disadvantages**: Some COCs might increase the risk of seizures slightly, although the risk is generally low, especially with levetiracetam.
   - **Preferred Option**: Low-dose COC containing 20-35 mcg of ethinylestradiol with a second-generation progestin like levonorgestrel is often recommended due to its lower thrombotic risk and compatibility with AEDs.
   - **Consideration**: Ensure she understands the importance of adherence, as missed doses can reduce effectiveness.

2. **Progestin-Only Pill (POP)**:

- **Advantages**: Progestin-only pills, or "mini-pills," are less likely to interfere with epilepsy but must be taken at the same time daily, as they have a shorter window of effectiveness compared to COCs.
- **Disadvantages**: Irregular bleeding can be a side effect, and some users find the strict timing challenging.
- **Preferred Option**: Desogestrel-containing POPs may be slightly more forgiving with timing and are a good option if she is open to trying a progestin-only approach.

3. **Non-Hormonal Options**:
- Non-hormonal options like copper intrauterine devices (IUDs) might be considered in cases where hormonal interactions are a concern, but they may not be suitable here due to her needle aversion and lack of a current need for long-term contraception.

Preferred Treatment Based on Guidelines:

Based on the European and international guidelines for contraception in individuals with epilepsy:

1. **Low-dose COC with Levonorgestrel and Ethinylestradiol** is preferred as it combines efficacy, compatibility with her epilepsy medication, and aligns with her preferences.
2. **Education and Counseling**: It is essential to educate her about the need for daily adherence, potential side effects, and address any concerns she may have, given her developmental history.

Follow-up:

- **Initial Follow-Up**: Schedule a follow-up visit after three months to assess tolerability, manage any side effects, and monitor for any changes in her menstrual cycle or seizure frequency.
- **Seizure Monitoring**: Although levetiracetam typically does not interact with COCs, advise her to monitor for any unusual symptoms and report them promptly.

Addendum: Case 5 Therapeutic Case 5: Diabetes

Chat GPT 3.5

A Belgian 68 year old male, visits the general practitioner for a yearly checkup.
Symptoms and complaints: None, yearly blood control
Physical examination: Normal lung auscultation, Cor auscultation regular rhythm wit a murmur. Blood pressure 120/55mmHg
Technical examination: Total cholesterol 77 mg/dL ; HDL-cholesterol - 36 mg/dL; Non-HDL-cholesterol 41 mg/dL; Ratio total-cholesterol:HDL-cholesterol 2,14 mg/mg; LDL cholesterol 19 mg/dL; Triglycerides 112 mg/dL; Hb A1c 8,0 %; Hb A1c (IFCC) + 63 mmol/mol; Glucose 217 mg/dL

Medical history: atrial fibrillation (2022), coronary bypass (2022), cholecystectomy (2017), Diabetes type 2 with microalbuminuria (2009), depression (2020), viral pancreatitis (1985)
Medication use: Aspirine 80 mg 1 daily, Olmesartan 20 mg 1 daily, Bisoprolol 2.5 mg 1 daily, rosuvastatin/ezetemibe 40/10 mg 1 daily, venlafaxin 150 mg 1 daily, sitagliptin 100 mg 1 daily, Metformine 850 mg 3 daily, gliclazide 60 mg 1 daily, pantoprazole 20 mg 1 daily, Spironolactone 25 1 daily

Give the possible treatment options and the preferred treatment. Be specific and incorporate any applicable guidelines

Answer 2024-01-13

The patient, a 68-year-old Belgian male, presents with a medical history including atrial fibrillation, coronary bypass surgery, cholecystectomy, type 2 diabetes with microalbuminuria, depression, and a history of viral pancreatitis. The current visit is for a yearly checkup with no specific complaints, but the patient is on multiple medications, and the latest blood work and examination show some concerning values.

1. **Atrial Fibrillation (AF):**
   - The patient has a history of AF (2022). The current treatment includes Bisoprolol (beta-blocker) and Olmesartan (angiotensin II receptor blocker). Anticoagulation therapy should be considered, especially given the patient's history of coronary artery disease and atrial fibrillation. The CHA2DS2-VASc score should be calculated to assess the risk of stroke.

2. **Coronary Artery Disease (CAD):**
   - The patient had coronary bypass surgery in 2022. The current treatment with Aspirin, Bisoprolol, and rosuvastatin/ezetimibe is appropriate for secondary prevention. The blood pressure target should be maintained below 130/80 mmHg.

3. **Type 2 Diabetes:**
   - The patient has uncontrolled diabetes with an HbA1c of 8.0%. The current treatment includes Metformin, gliclazide, and sitagliptin. The American Diabetes Association (ADA) recommends an individualized approach, but intensification of therapy may be needed. Consider adjusting the current antidiabetic regimen or adding insulin therapy.

4. **Depression:**
   - The patient is on venlafaxine for depression. Review the mental health status and consider referral to a mental health professional for further evaluation and management if needed.

5. **Dyslipidemia:**
   - The lipid profile shows low total cholesterol, low LDL cholesterol, and low HDL cholesterol levels. Given the patient's history of CAD, aggressive lipid-lowering therapy with rosuvastatin/ezetimibe is appropriate. Regular monitoring of liver function tests and creatine kinase is essential.

6. **Microalbuminuria:**
   - Ongoing monitoring of microalbuminuria is crucial. Blood pressure control with Olmesartan and Spironolactone can be beneficial.

7. **Pancreatitis History:**
   - Consider reviewing the patient's history of viral pancreatitis and ensuring that there are no ongoing issues related to pancreatic function.

8. **Overall Medication Review:**
   - Evaluate the need for each medication, considering potential interactions and side effects. In particular, assess the necessity of pantoprazole, considering the risk of long-term proton pump inhibitor use.

9. **Lifestyle Modifications:**
   - Reinforce the importance of lifestyle modifications, including a heart-healthy diet, regular exercise, smoking cessation, and moderation of alcohol intake.

Preferred Treatment:
- Adjust antidiabetic therapy to improve glycemic control. Consider insulin therapy.
- Initiate anticoagulation therapy for stroke prevention in atrial fibrillation.
- Ensure optimal secondary prevention measures for coronary artery disease.
- Regularly monitor lipid profile, liver function, and creatine kinase levels due to the use of rosuvastatin/ezetimibe.
- Evaluate the need for each medication in the current regimen, with a focus on deprescribing where appropriate.

This patient's complex medical history necessitates an individualized and multidisciplinary approach, involving collaboration between the general practitioner, cardiologist, endocrinologist, and mental health professional. Regular follow-up and monitoring are essential to adjust the treatment plan as needed.

Answer 2024-02-27

Based on the provided medical history, physical examination, and laboratory findings, here are the possible treatment options and the preferred treatment for the patient:

1. **Management of Diabetes Type 2 with Poor Glycemic Control**:
   - Given the patient's HbA1c level of 8.0% (63 mmol/mol) and elevated glucose level of 217 mg/dL, it indicates poor glycemic control.
   - The current treatment regimen includes metformin, sitagliptin, and gliclazide, but it seems insufficient.

- Preferred Treatment Option: Consider intensifying the diabetes treatment regimen. Adding or adjusting the dosage of another anti-diabetic medication such as a GLP-1 receptor agonist or a SGLT-2 inhibitor could be beneficial. The American Diabetes Association (ADA) guidelines recommend individualized therapy to achieve target HbA1c levels (<7% for most adults).

2. **Cardiovascular Risk Reduction**:
   - The patient has a history of atrial fibrillation, coronary bypass surgery, and is on treatment with aspirin, olmesartan, bisoprolol, and rosuvastatin/ezetimibe. Despite the low LDL cholesterol (19 mg/dL), the patient still has residual cardiovascular risk, as indicated by the presence of atrial fibrillation and the history of coronary artery disease.
   - Preferred Treatment Option: Continue current cardiovascular medications for secondary prevention. Aspirin for antiplatelet therapy, olmesartan and bisoprolol for blood pressure control, and rosuvastatin/ezetimibe for cholesterol management. Additionally, optimizing lifestyle factors such as diet and exercise is essential. Consideration of anticoagulation therapy may also be necessary depending on the CHA2DS2-VASc score for stroke risk assessment in atrial fibrillation, according to guidelines such as those from the American College of Cardiology (ACC) and the American Heart Association (AHA).

3. **Depression Management**:
   - The patient has a history of depression and is currently on venlafaxine.
   - Preferred Treatment Option: Continue venlafaxine for depression management. Consideration of therapy and regular follow-ups with a mental health professional are essential for monitoring and adjusting treatment as needed.

4. **Pancreatic Health and Gastrointestinal Protection**:
   - The patient has a history of viral pancreatitis and cholecystectomy, and is currently on pantoprazole.
   - Preferred Treatment Option: Continue pantoprazole for gastrointestinal protection. Encourage lifestyle modifications to reduce the risk of pancreatitis recurrence, such as avoiding alcohol and maintaining a healthy weight.

5. **Microalbuminuria and Renal Protection**:
   - The patient has a history of microalbuminuria associated with diabetes.
   - Preferred Treatment Option: Continue current medications for diabetes management, as they have renal protective effects. Regular monitoring of renal function and urine albumin levels is essential.

Preferred Treatment Summary:
- Intensify diabetes treatment regimen to achieve better glycemic control, considering adding GLP-1 receptor agonist or SGLT-2 inhibitor.
- Continue current cardiovascular medications for secondary prevention.
- Continue venlafaxine for depression management.
- Continue pantoprazole for gastrointestinal protection.
- Monitor renal function and urine albumin levels regularly.

Answer 2024-04-30

Given the medical history and current health parameters of the patient, several treatment options and considerations can be recommended:

1. **Control of Blood Glucose (Diabetes Management)**:

- The elevated HbA1c and glucose levels indicate inadequate control of diabetes. The current medications (metformin, sitagliptin, gliclazide) may need adjustment.
- The American Diabetes Association (ADA) recommends a personalized approach to diabetes management, aiming for an HbA1c target of <7% in most adults to reduce the risk of microvascular complications like nephropathy and retinopathy.

2. **Cardiovascular Risk Management**:
- Despite low LDL cholesterol levels due to rosuvastatin/ezetimibe, the patient has a complex cardiovascular history with atrial fibrillation and prior coronary bypass.
- The European Society of Cardiology (ESC) guidelines emphasize intensive lipid-lowering therapy in high-risk patients. Considering the patient's risk factors, optimizing statin therapy is crucial.

3. **Hypertension and Atrial Fibrillation**:
- The patient is on olmesartan (an angiotensin II receptor blocker) and bisoprolol (a beta-blocker) for blood pressure control and atrial fibrillation.
- Blood pressure should be closely monitored to maintain within recommended targets (usually <130/80 mmHg for patients with diabetes and cardiovascular disease).

4. **Depression**:
- The patient is on venlafaxine for depression, which should be managed in conjunction with mental health professionals.
- Regular monitoring for antidepressant efficacy and side effects is essential.

Preferred Treatment Strategy:
- **Diabetes Management**: Given the patient's uncontrolled diabetes, consideration should be given to intensifying therapy. This may involve optimizing current medications (e.g., adjusting metformin or adding insulin) and emphasizing lifestyle modifications.

- **Cardiovascular Risk**: Considering the patient's complex history, an assessment of overall cardiovascular risk and optimization of lipid-lowering therapy (e.g., potentially increasing the dose of rosuvastatin/ezetimibe) is important.

- **Hypertension and Atrial Fibrillation**: Blood pressure control should be maintained within recommended targets. Adjustments to current medications may be necessary based on regular monitoring.

- **Depression**: Regular mental health assessments are essential to ensure the effectiveness of venlafaxine and to address any changes in the patient's mental health status.

It's crucial for the patient to have regular follow-up visits with healthcare providers (general practitioner, cardiologist, endocrinologist, and psychiatrist) to coordinate care and optimize management strategies, considering the patient's complex medical history and multiple comorbidities. Treatment decisions should be individualized based on the patient's specific circumstances and preferences.

Chat GPT 4.0

Answer 2024-11-05

Based on the findings from the check-up, particularly the elevated HbA1c level, glucose, and cholesterol levels, as well as the patient's history of diabetes, atrial fibrillation, and coronary artery disease, there are a few areas to focus on for treatment and management:

1. **Diabetes Management:**
   - The HbA1c level of 8.0% (63 mmol/mol) indicates suboptimal glycemic control. The target HbA1c for most adults with diabetes, according to ADA guidelines, is generally <7%, but this target can vary based on individual factors, comorbidities, and life expectancy.
   - **Medication Adjustment:**
     - Consider intensifying diabetes management. Adding a **GLP-1 receptor agonist** (e.g., liraglutide or semaglutide) or **SGLT-2 inhibitor** (e.g., empagliflozin or dapagliflozin) could be beneficial, especially considering his cardiovascular history, as both drug classes offer cardiovascular protection in patients with type 2 diabetes.
     - Assess the current dose of **metformin** and **gliclazide** in combination with sitagliptin. If glucose control remains inadequate with current treatment, replacing sitagliptin with a GLP-1 agonist or SGLT-2 inhibitor may be more effective and could help reduce cardiovascular risk.
     - Monitor renal function closely if SGLT-2 inhibitors are added, as they are typically indicated for patients with preserved renal function (eGFR >45 ml/min/1.73 m² for most agents).

2. **Cholesterol Management:**
   - While LDL cholesterol is very low (likely due to current use of high-dose **rosuvastatin/ezetimibe**), consider evaluating **lipid management goals** given his low HDL levels and triglycerides.
   - Adding or intensifying lifestyle interventions could be beneficial to help increase HDL, though medication adjustments for HDL are generally not the primary focus in high-risk patients.
   - Continue the current regimen but maintain monitoring.

3. **Blood Pressure and Cardiovascular Risk:**
   - Blood pressure is within a reasonable range (120/55 mmHg) with the use of **olmesartan, bisoprolol,** and **spironolactone**, so no adjustments appear necessary at this point.
   - Given his history of atrial fibrillation, assess anticoagulation therapy adequacy. He is on **aspirin** (80 mg), but this might not provide sufficient protection for stroke prevention. Consider switching to an oral anticoagulant such as **warfarin** or a **DOAC** (e.g., apixaban, rivaroxaban) if not contraindicated, as these are generally preferred for atrial fibrillation-related stroke prevention in high-risk patients.

4. **Mental Health:**
   - Monitor for any signs of depression relapse, especially given the history and the ongoing treatment with **venlafaxine**. Adjustments might not be needed unless symptoms recur, but regular assessments would be prudent.

5. **Lifestyle Modifications:**
   - Reinforce lifestyle changes, focusing on dietary adjustments, weight management, and physical activity, especially to improve glycemic control, maintain blood pressure, and potentially increase HDL.

Preferred Treatment Plan:

1. **Switch aspirin to an oral anticoagulant (DOAC)** to manage atrial fibrillation and reduce stroke risk.
2. **Consider adding a GLP-1 agonist or SGLT-2 inhibitor** to the diabetes regimen for better glycemic control and cardiovascular protection.
3. **Continue current lipid and blood pressure medications** with close monitoring, as lipid levels and blood pressure appear under control.
4. **Regular follow-ups** for diabetes management, mental health, and cardiovascular risk, ensuring comprehensive monitoring and potential dose adjustments as needed.

This treatment plan aligns with current guidelines for managing type 2 diabetes, atrial fibrillation, and cardiovascular disease. Regular follow-up will be essential to reassess the efficacy and safety of the medications, monitor renal function, and evaluate any necessary adjustments.

Answer 2024-11-07

Given this patient's history, physical examination, and lab results, let's outline the potential treatment options, with a focus on cardiovascular and metabolic risk management, in line with clinical guidelines and best practices.

1. **Diabetes Management**

- **Current Status**: The patient’s HbA1c is elevated (8.0%), indicating suboptimal glycemic control. Current medications include metformin, sitagliptin, and gliclazide.

- **Treatment Adjustment Options**:
  - **Consider adding an SGLT2 inhibitor** (e.g., empagliflozin or dapagliflozin): These drugs are beneficial for type 2 diabetes, especially in patients with cardiovascular disease and renal impairment (microalbuminuria is present). SGLT2 inhibitors can improve glucose control and may provide renal and cardiovascular protection.
  - **GLP-1 receptor agonist** (e.g., liraglutide or semaglutide) could also be considered. These agents are beneficial in reducing HbA1c, promoting weight loss, and offering cardiovascular benefits. This could be particularly helpful given the patient's established cardiovascular disease.

- **Guideline Recommendations**: According to the ADA and ESC guidelines, a combination of metformin, SGLT2 inhibitor, and/or GLP-1 receptor agonist is recommended for patients with diabetes and cardiovascular disease.

- **Preferred Treatment**: Initiate an SGLT2 inhibitor, as it will address both glycemic control and cardiovascular risk.

2. **Cardiovascular Risk Management**

- **Current Status**: The patient has a history of atrial fibrillation, coronary bypass surgery, and uses aspirin for secondary prevention. The lipid profile shows very low LDL (likely due to rosuvastatin/ezetimibe), which is appropriate given the cardiovascular history. Blood pressure is within a favorable range on olmesartan, bisoprolol, and spironolactone.

- **Anticoagulation for Atrial Fibrillation**: Atrial fibrillation (AF) with a history of coronary artery disease generally warrants anticoagulation for stroke prevention. Given his current medication, it’s unclear if he's on any anticoagulation beyond aspirin. **Consider adding an

oral anticoagulant (e.g., a direct oral anticoagulant like apixaban)** if no contraindications are present, as this would reduce stroke risk.

- **Preferred Treatment**: Start a direct oral anticoagulant (e.g., apixaban), with dose adjustment as necessary for renal function, which should be monitored given the patient's diabetes.

3. **Lipid Management**

- **Current Status**: The patient's LDL is very low, which is favorable for secondary prevention in cardiovascular disease patients.

- **Guideline Recommendations**: No adjustments are needed if the patient is tolerating rosuvastatin/ezetimibe well, as his lipid profile is in line with the ESC/EAS target recommendations for very high-risk patients (LDL-C <55 mg/dL).

- **Preferred Treatment**: Continue current therapy without change.

4. **Blood Pressure Management**

- **Current Status**: Blood pressure is 120/55 mmHg, which is within target. The patient is currently on olmesartan, bisoprolol, and spironolactone.

- **Guideline Recommendations**: According to ESC/ESH guidelines, no adjustment is required as the patient's blood pressure is within target.

- **Preferred Treatment**: Continue current antihypertensive therapy without changes.

5. **Microalbuminuria**

- **Current Status**: Microalbuminuria is present, indicating early diabetic kidney disease.

- **Management**:
  - SGLT2 inhibitors, as noted, are beneficial in reducing albuminuria and slowing kidney disease progression.
  - Ensure optimization of blood pressure and glycemic control as discussed.

6. **Mental Health**

- **Current Status**: The patient is on venlafaxine for depression and seems to be stable.

- **Preferred Treatment**: Continue current mental health treatment with venlafaxine unless new symptoms arise.

Summary of Preferred Treatment

1. **Add an SGLT2 inhibitor** to improve glycemic control and provide renal and cardiovascular benefits.
2. **Introduce an oral anticoagulant (e.g., apixaban)** for atrial fibrillation to reduce stroke risk.
3. **Continue current lipid, blood pressure, and mental health management** without changes.

This approach aligns with current ADA, ESC, and EAS guidelines for patients with diabetes, cardiovascular disease, and a history of atrial fibrillation. Regular follow-up for blood pressure, kidney function, and HbA1c is recommended to monitor the effectiveness of these adjustments.

Answer 2024-11-09

Based on this patient's profile, several treatment considerations emerge, particularly in managing diabetes, dyslipidemia, and atrial fibrillation risk due to the history of cardiovascular events. Here's a comprehensive approach based on current guidelines:

1. **Diabetes Management:**
- **Current Status:** HbA1c is at 8.0% (63 mmol/mol), indicating suboptimal glycemic control. This is a priority area due to type 2 diabetes with microalbuminuria and existing cardiovascular disease.
- **Recommendations:**
    - **Intensify glycemic control:** This could involve optimizing current medications or introducing GLP-1 receptor agonists (e.g., liraglutide or semaglutide) or SGLT2 inhibitors (e.g., empagliflozin or dapagliflozin), both of which have shown cardiovascular and renal benefits in diabetes with cardiovascular disease. The choice depends on patient tolerance, kidney function, and costs.
    - **Reduce HbA1c target:** Aim for an individualized target around 7% (if achievable without hypoglycemia risk), with an emphasis on reducing hyperglycemic episodes.

2. **Lipid Management:**
- **Current Status:** LDL is exceptionally low (19 mg/dL), likely due to rosuvastatin/ezetimibe therapy. While low LDL levels are beneficial in atherosclerotic cardiovascular disease (ASCVD), levels under 25 mg/dL should be monitored for any adverse effects.
- **Recommendations:**
    - **Consider maintaining current lipid therapy** if no side effects occur, as this low LDL is aligned with secondary prevention goals in high-risk patients.
    - **Guidelines:** ESC and AHA guidelines recommend an LDL target of <55 mg/dL in very high-risk patients (e.g., established ASCVD, diabetes, microalbuminuria), so the current regimen is appropriate.

3. **Blood Pressure Management:**
- **Current Status:** BP is 120/55 mmHg, which is within the goal for this patient, considering the cardiovascular risk profile.
- **Recommendations:**
    - **Continue current antihypertensive therapy:** Olmesartan and Bisoprolol appear effective. Routine monitoring should continue.

4. **Antithrombotic Therapy (Atrial Fibrillation and Secondary Prevention):**
- **Current Status:** The patient is on low-dose aspirin (80 mg daily).
- **Recommendations:**
    - **Re-evaluate anticoagulation:** Given atrial fibrillation history and the CHADS-VASc score (likely >2), this patient is at increased risk of thromboembolic events. Oral anticoagulation (e.g., a direct oral anticoagulant such as apixaban or rivaroxaban) may be preferable over aspirin. However, the balance of bleeding risk and patient tolerance must be evaluated.
    - **Guidelines:** Current ESC guidelines favor anticoagulation for AF patients with a history of ASCVD over antiplatelet therapy alone.

5. **Further Monitoring and Supportive Care:**
- **Diabetic kidney disease:** Continue monitoring kidney function (e.g., serum creatinine, eGFR) and microalbuminuria levels. Spironolactone is appropriate for cardiovascular risk reduction and may help with proteinuria but should be monitored due to its potential impact on potassium.
- **Lifestyle and Mental Health Support:** Depression (treated with venlafaxine) and diabetes management can benefit from continued psychological and dietary support. Referral to diabetes education and mental health resources may aid in adherence and improve quality of life.
- **Gastrointestinal Protection:** Pantoprazole should be continued for gastroprotection given polypharmacy and past cholecystectomy.

Preferred Treatment Summary:
- **Introduce a GLP-1 receptor agonist or SGLT2 inhibitor** to improve glycemic control and reduce cardiovascular and renal risk.
- **Switch to or add an oral anticoagulant** for better protection against stroke due to atrial fibrillation.
- **Maintain current lipid and blood pressure regimen**, given the target achievements.

Regular follow-up and patient-centered education are crucial to monitor for potential side effects or drug interactions, especially with the introduction of new therapies.